quinazolines has been researched along with triazoles in 315 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 8 (2.54) | 18.7374 |
| 1990's | 54 (17.14) | 18.2507 |
| 2000's | 115 (36.51) | 29.6817 |
| 2010's | 119 (37.78) | 24.3611 |
| 2020's | 19 (6.03) | 2.80 |
| Authors | Studies |
|---|---|
| Kottke, K; Kühmstedt, H | 2 |
| O'Regan, MH; Perkins, LM; Phillis, JW; Simpson, RE | 1 |
| Cox, BF; Lappe, RW; Sheldon, JH | 1 |
| Adén, U; Fredholm, BB; Johansson, B; Lindström, K; Svenningsson, P | 1 |
| Abels, BC; Branch, RA; Callis, JT; Sabra, R | 1 |
| Griebel, G; Misslin, R; Vogel, E | 1 |
| Barbaz, BS; Bernard, PS; Braunwalder, AF; Cash, WD; Francis, JE; Friedmann, RC; Hyun, JL; Loo, PS; Lovell, RA; Mazzenga, GC | 1 |
| Barraco, RA; Phillis, JW | 1 |
| Holtzman, SG; Mumford, GK | 1 |
| Holtzman, SG | 3 |
| Czuczwar, SJ; Janusz, W; Kleinrok, Z; Szczepanik, B | 1 |
| Do, UH; Jarvis, MF; Sills, MA; Williams, M | 1 |
| Bourguignon, JJ; Griebel, G; Misslin, R; Remmy, D; Saffroy-Spittler, M; Vogel, E | 1 |
| Brown, GL; Douglas, FL; Kotake, AN; Mustafa, SJ; Sabouni, MH | 1 |
| Behnke, N; Müller, W; Neumann, J; Schmitz, W; Scholz, H; Stein, B | 1 |
| Gewirtz, H; Mills, I | 1 |
| Brubaker, WF; Williams, ED | 1 |
| Abels, BC; Branch, KR; Branch, RA; Callis, JT; Jackson, EK; Kuan, CJ; Sabra, R | 1 |
| Braunwalder, A; Cash, WD; Francis, J; Ghai, G; Psychoyos, S; Stone, GA; Williams, M | 1 |
| Atkins, C; Cash, WD; Francis, JE; Friedmann, RC; Furness, P; Ghai, G; Hyun, JL; Psychoyos, S; Warren, V; Wenk, P | 1 |
| Cote, DT; Dotson, RA; Francis, JE; Ghai, G; Goodman, FR; Hopkins, MF; Williams, M; Zimmerman, MB | 1 |
| Hagen, V; Kottke, K; Kühmstedt, H; Renner, H; Schnitzler, S | 1 |
| Karasawa, A; Kishibayashi, N; Suzuki, M; Tomaru, A | 1 |
| Amoroso, S; Annunziato, L; Di Renzo, G; Iannotti, E; Saggese, ML | 1 |
| Howell, LL; Landrum, AM | 1 |
| Howell, LL | 1 |
| Imaizumi, M; Miyazaki, S; Onodera, K | 1 |
| Cazin, L; Mei, YA; Vaudry, H | 1 |
| Jarvis, JE; Reeves, JJ; Sheehan, MJ; Strong, P | 1 |
| Borchard, U; Felsch, A; Stöcker, K | 1 |
| Patel, M; Sheehan, MJ; Strong, P | 1 |
| Gao, Y; Phillis, JW | 1 |
| Schmitz, W; Scholz, H; Seeland, C; Stein, B | 1 |
| Conti, A; Dionisotti, S; Gatta, F; Ongini, E; Sandoli, D; Zocchi, C | 1 |
| Currin, RT; Lemasters, JJ; Lichtman, SN; Reinstein, LJ; Thurman, RG; Wang, J | 1 |
| Byrd, LD; Howell, LL | 1 |
| Kroll, K; Schrader, J | 1 |
| Ahlberg, S; Fredholm, BB; Olsson, RA; Parkinson, FE; van der Ploeg, I | 1 |
| Baraldi, PG; Dionisotti, S; Ferrara, S; Ongini, E; Zocchi, C | 1 |
| di Chiara, G; Morelli, M; Pinna, A; Wardas, J | 1 |
| Dobson, JG; Fenton, RA; Sawmiller, DR | 1 |
| Jacobson, KA; Ji, XD; Kim, YC | 1 |
| Anderson, GF; Barraco, RA; Helfman, CC | 1 |
| Aly, AA; Hassan, AA; Mohamed, NK; Mourad, AF | 1 |
| Dobson, JG; Ethier, MF | 1 |
| Abbracchio, MP; Jacobson, KA; Jiang, JL; Kim, YC; Sei, Y; Yao, Y | 1 |
| Jones, CA; Reeves, JJ; Sheehan, MJ; Vardey, CJ; Whelan, CJ | 1 |
| Alexander, SP; Cooper, J; Hill, SJ | 1 |
| Algueró, M; Bartroli, J; Boncompte, E; Conte, L; Forn, J; García-Rafanell, J; Merlos, M; Ramis, J; Turmo, E; Vericat, ML | 1 |
| Chang, L; de Zwart, M; IJzerman, AP; Jacobson, KA; Kim, YC; Melman, N; Moro, S; von Frijtag Drabbe Künzel, JK | 1 |
| Baraldi, PG; Borea, PA; Cacciari, B; Dionisotti, S; Ongini, E; Varani, K | 1 |
| Cutler, BS; Dobson, JG; Fenton, RA; Li, Jm; Peyton, BD; Powell, CC; Wheeler, HB | 1 |
| Dionisotti, S; Fredholm, BB; Gessi, S; Irenius, E; Ongini, E | 1 |
| Fredholm, BB; Johansson, B; Kuzmin, A; Zvartau, EE | 1 |
| Hata, K; Kloner, RA; Przyklenk, K; Whittaker, P | 1 |
| Cuenca-Estrella, M; Monzón, A; Ramos, G; Rodríguez-Tudela, JL | 1 |
| Aboulwafa, OM; el-Azzouni, MZ; el-Mansoury, ST; el-Tombary, AA; Ismail, KA; Omar, AM | 1 |
| Fredholm, BB; Lindström, K | 1 |
| Borgeat, P; Bourgoin, SG; Harbour, D; Naccache, PH; Thibault, N | 1 |
| Jacobson, KA; Ji, XD; Lvovskiy, D; Melman, N; Webb, TR | 1 |
| Curry, B; Curwen, JO; Dukes, M; Hennequin, LF; Kendrew, J; Ogilvie, DJ; Richmond, GH; Stokes, ES; Thomas, AP; Wadsworth, PF; Wedge, SR | 1 |
| Gean, PW; Lu, KT; Wu, SP | 1 |
| Abbracchio, MP; Barbieri, D; Brambilla, R; Cattabeni, F; Ceruti, S; Franceschi, C; Jacobson, KA; Kim, YC; Klotz, KN; Lohse, MJ | 1 |
| Barili, PL; Bertelli, L; Biagi, G; Giannaccini, G; Giorgi, I; Livi, O; Lucacchini, A; Manera, C; Scartoni, V | 1 |
| Bar-Yehuda, S; Barer, F; Farbstein, T; Fishman, P; Ohana, G | 1 |
| Abebe, W; Mozaffari, MS; Warren, BK | 1 |
| Clark, KL; Guyton, RA; Nakamura, M; Velez, DV; Vinten-Johansen, J; Zhao, ZQ | 1 |
| Ogilvie, DJ; Wedge, SR | 1 |
| Bartrolí, J; Lira, R; Urbina, JA; Visbal, G | 1 |
| Brand, A; Eschke, D; Nieber, K; Vissiennon, Z | 1 |
| Khoo, HE; Mittal, RA; Tan, CH | 1 |
| Coyne, EF; Meno, JR; Ngai, AC; West, GA; Winn, HR | 1 |
| Carrillo, AJ; Guarro, J | 1 |
| Broadley, KJ; Spruntulis, LM | 1 |
| Chen, Y; Hertz, L; Rathbone, MP | 1 |
| Capilla, J; Guarro, J; Ortoneda, M; Pastor, FJ | 1 |
| Hamann, M; Richter, A | 1 |
| Baldwin, SA; Cass, CE; Duszyk, M; Man, SF; Ng, AM; Sawicka, J; Szkotak, AJ; Young, JD | 1 |
| Ashton, K; Berr, SS; Cerniway, RJ; Harrison, GJ; Headrick, JP; Paul Matherne, G; Peart, J; Regan, S | 1 |
| Ijzerman, AP; Timmerman, H; van Muijlwijk-Koezen, JE | 1 |
| Urbina, JA | 1 |
| Jacobson, KA; Jacobson, MA; Ledent, C; Morrison, RR; Mustafa, SJ; Talukder, MA | 1 |
| Bivalacqua, TJ; Champion, HC; Kadowitz, PJ; Lambert, DG | 1 |
| Anderson, KE; Daniele, N; Foukas, LC; Jensen, J; Ktori, C; Shepherd, PR | 1 |
| Eppinger, E; Meinhardt, G; Schmidmaier, R | 1 |
| Bruneteau, G; Clément, O; Cuénod, CA; Frija, G; Frouin, F; Kahn, E; Pradel, C; Siauve, N | 1 |
| Le Crom, S; Prou, D; Vernier, P | 1 |
| Ezeamuzie, CI; Philips, E | 1 |
| Feldkamp, T; Heemann, U; Herget-Rosenthal, S; Horbelt, M; Kribben, A; Lange, B; Philipp, T; Pietruck, F | 1 |
| Griffiths, RR; Weerts, EM | 1 |
| Choi, JI; Jeong, SW; Yoon, MH | 1 |
| Saccone, GT; Toouli, J; Woods, CM | 1 |
| Hague, BF; Kindt, TJ; Zhao, TM | 1 |
| Barber, I; Tarrant, KA; Thompson, HM | 1 |
| Capilla, J; Fernández, B; Guarro, J; Mayayo, E; Ortoneda, M; Pastor, FJ; Yustes, C | 1 |
| del Palacio, A; Garau, M; Pereiro, M | 1 |
| Checkley, D; Curry, B; Dukes, M; Kendrew, J; Middleton, B; Tessier, JJ; Waterton, JC; Wedge, SR | 1 |
| Baur, F; Fozard, JR; Wolber, C | 1 |
| O'Regan, MH; Phillis, JW | 1 |
| Chen, A; Gao, ZG; Gross, AS; Jacobson, KA; Kim, SK; Van Calenbergh, S; Van Rompaey, P | 1 |
| Bruneteau, G; Clement, O; Cuenod, CA; de Bazelaire, C; Frija, G; Frouin, F; Pradel, C; Robert, PH; Siauve, N; Tessier, JL; Wedge, SR | 1 |
| Catarzi, D; Colotta, V; Filacchioni, G; Lucacchini, A; Martini, C; Trincavelli, L; Varano, F | 1 |
| El-Bendary, ER; Gineinah, MM; Nasr, MN | 1 |
| Bartroli, J; Benjamin, DK; Boyce, M; Miller, JL; Perfect, JR; Schell, WA; Toffaletti, DL; Wills, EA | 1 |
| Capilla, J; Guarro, J; Javier Pastor, F; Ortoneda, M; Pujol, I | 1 |
| Bremer, HC; Elsner, P; Girolomoni, G; Herouy, Y; Idzko, M; Mockenhaupt, M; Norgauer, J; Panther, E; Sorichter, S; Windisch, W | 1 |
| Belloc, J; Parella, T; Sánchez-Ferrando, F | 1 |
| Li, H; Lloyd, PG; Prior, BM; Terjung, RL; Yang, HT | 1 |
| Fernández-Torres, B; Guarro, J; Lazéra, Mdos S; Trilles, L; Wanke, B | 1 |
| Afonso, LC; Bahia, MT; Chiari, E; de Lana, M; Guedes, PM; Machado-Coelho, GL; Tafuri, WL; Urbina, JA; Veloso, VM | 1 |
| Bennett, MR; Lin, YQ | 2 |
| Beex, L; Come, SE; Jones, SE; Kaufmann, M; Makris, A; Nortier, JW; Possinger, K; Robertson, JF; Rutqvist, LE | 1 |
| Kaplow, R | 1 |
| Baharav, E; Bar-Yehuda, S; Fishman, P; Halpren, M; Madi, L; Ochaion, A; Rath-Wolfson, L; Silberman, D; Weinberger, A | 1 |
| Alagarsamy, V; Giridhar, R; Yadav, MR | 2 |
| Andrisani, OM; Bilodeau, ML; Ji, M; Paris, M | 1 |
| Sladek, CD; Song, Z | 1 |
| Ali, S; Barrett, N; Beresford, E; Coombes, RC; Hadjiminas, D; Jiang, J; Mansi, JL; Morrison, K; Peston, D; Polychronis, A; Shivapatham, D; Shousha, S; Singhal, H; Sinnett, HD; Slade, MJ; Vigushin, D | 1 |
| Cavalheiro, EA; da Silva Fernandes, MJ; Doná, F; Ferreira, AT; Vianna, EP | 1 |
| Jantová, S; Letasiová, S; Ovádeková, R; Spirková, K; Stankovský, S | 1 |
| Hough, LB; Lu, Q; Montero, MJ; Nalwalk, JW; Shan, Z; Svokos, K; Wentland, MP | 1 |
| Baró-Tomás, T; Jiménez-Cabello, T; Morera-López, Y; Torres-Rodríguez, JM | 1 |
| Di Maira, G; Frascella, P; Lucchini, V; Mazzorana, M; Meggio, F; Pagano, MA; Pinna, LA; Ruzzene, M; Sarno, S; Zambon, A | 1 |
| Cortés, D; Díaz-Cruz, A; Guinzberg, R; Piña, E; Riveros-Rosas, H; Villalobos-Molina, R | 1 |
| Holý, A; Kmonícková, E; Potmesil, P; Zídek, Z | 1 |
| Bacilieri, M; Bolcato, C; Cacciari, B; Moro, S; Pastorin, G; Spalluto, G | 1 |
| Gao, ZG; Jacobson, KA; Moro, S; Spalluto, G | 1 |
| Coppi, E; Corradetti, R; Pedata, F; Pugliese, AM; Spalluto, G | 1 |
| Broadley, KJ; Clark, JH; James, S; Kidd, EJ; Martin, TJ; Yates, L | 1 |
| Jantová, S; Labuda, J; Ovádeková, R; Theiszová, M | 1 |
| Borioni, A; Del Giudice, MR; Ferretti, R; Mustazza, C; Rodomonte, A; Sbraccia, M; Sestili, I | 1 |
| Alves, SH; Azevedo, AC; Boff, E; Da Matta, DA; Guarro, J; Loreto, ES; Santurio, JM | 1 |
| Holý, A; Kmonícková, E; Krecmerová, M; Potmesil, P; Zídek, Z | 1 |
| Jantová, S; Letasiová, S; Múcková, M; Ovádeková, R | 1 |
| Mulè, F; Serio, R; Zizzo, MG | 1 |
| Attoub, S; Bruyneel, E; Emami, S; Gespach, C; Grijelmo, C; Nguyen, QD; Rivat, C; Rodrigue, CM; Rodrigues, S | 1 |
| Balvay, D; Bessoud, B; Bois, FY; Brochot, C; Cuénod, CA; Siauve, N | 1 |
| Cano, J; Gené, J; Gilgado, F; Guarro, J; Serena, C | 1 |
| Gao, C; Gao, N; Hu, HZ; Liu, S; Wood, JD; Xia, Y | 1 |
| Carlini, P; Ciccarese, M; Cognetti, F; Fabi, A; Felici, A; Ferretti, G; Milella, M; Nuzzo, C; Papaldo, P; Ruggeri, EM | 1 |
| Farhangi, E; Rahmati, A; Shaabani, A | 1 |
| Cipak, L; Jantova, S; Letasiova, S; Repicky, A | 1 |
| Galzi, JL; Hachet-Haas, M; Kellenberger, E; Parmentier, M; Rognan, D; Springael, JY | 1 |
| Battastini, AM; Bavaresco, L; Bernardi, A; Delgado-Cañedo, A; Jacques-Silva, MC; Lenz, G; Wink, MR | 1 |
| Clark, E; Detre, S; Dowsett, M; Llombart, A; Magill, P; Mayordomo, JI; Salter, J; Skene, A; Smith, IE; Walsh, G | 1 |
| Ballard, P; Barlaam, BC; Bradbury, RH; Dishington, A; Hennequin, LF; Hickinson, DM; Hollingsworth, IM; Kettle, JG; Klinowska, T; Ogilvie, DJ; Pearson, SE; Scott, JS; Suleman, A; Whittaker, R; Williams, EJ; Wood, R; Wright, L | 1 |
| Alagarsamy, V; Kavitha, K; Meena, S; Rajesh, R; Rupeshkumar, M; Shankar, D; Siddiqui, AA | 1 |
| Denning, DW; Pasqualotto, AC | 1 |
| Chen, Z; Christofi, FL; Cooke, HJ; Grants, I; Melvin, WS; Mikami, DJ; Needleman, BJ; Wang, Y; Wunderlich, JE; Yu, JG | 1 |
| Arechavala, AI; Bianchi, MH; Negroni, R; Robles, AM; Santiso, G | 1 |
| Bode, AM; Christov, K; Ericson, ME; Grubbs, CJ; Juliana, MM; Lubet, RA; Steele, VE; Szabo, E | 1 |
| Ashina, M; Jensen, RH | 1 |
| Coe, IR; Naydenova, Z; Rose, JB | 1 |
| Conte, PF; Frassoldati, A; Giovannelli, S; Guarneri, V; Jovic, G; Oliva, C; Piacentini, F | 1 |
| Belli, C; Giovannini, M; Gregorc, V; Villa, E | 1 |
| Arya, N; Chu, QS; Cianfrocca, ME; Fleming, RA; Gale, M; Goldstein, LJ; Koch, KM; Loftiss, J; Murray, N; Pandite, L; Paul, E; Rowinsky, EK | 1 |
| Broadley, KJ; Smith, N | 1 |
| Charlton, ME; Kastan, MB; Rainey, MD; Stanton, RV | 1 |
| Arcella, A; Cantore, G; Di Gennaro, G; Esposito, V; Eusebi, F; Fredholm, BB; Fucile, S; Limatola, C; Manfredi, M; Martinello, K; Mascia, A; Miledi, R; Piccari, V; Quarato, PP; Roseti, C; Simonato, M | 1 |
| Ahlawat, R; Chavez-Valdez, R; Cristofalo, EA; Gauda, EB; Nathan, A; Wills-Karp, M | 1 |
| Barnett, J; Cuthbertson, A; Morrison, MS; Ricketts, SA; Tessier, J; Wedge, SR | 1 |
| Fricker, J | 1 |
| Miriel, VA; Rivers, RJ; Thengchaisri, N | 1 |
| Chen, Y; Gonzalez-Angulo, A; Guggisberg, N; Hennessy, B; Jorda, M; Mills, GB; Slingerland, JM; Tan, CK | 1 |
| Gaballah, K; Hills, A; Oakley, R; Partridge, M; Ryan, A | 1 |
| Elizondo, M; Garza-González, E; González, GM; González, JG; Robledo, E | 1 |
| Cipak, L; Jantova, S; Repicky, A | 1 |
| Baselga, J; Cortes, J | 1 |
| Dieras, V; Florance, A; Gomez, HL; Johnston, S; Kennedy, MJ; Lichinitser, M; Maltzman, J; Manikhas, A; O'Rourke, L; Oliva, C; Pegram, M; Pippen, J; Pivot, X; Press, MF; Romieu, G; Sadeghi, S; Stein, S | 1 |
| Aung, HH; Barnholt, KE; Kota, RS; Rutledge, JC | 1 |
| Antipenko, LN; Karpenko, AV; Katsev, AM; Komarovska-Porokhnyavets, EZ; Kovalenko, SI; Novikov, VP | 1 |
| Guarneri, V | 1 |
| Gayatri, G; Mani Chandrika, P; Murthy, US; Narsaiah, B; Pranay Kumar, K; Raghu Ram Rao, A; Yakaiah, T | 1 |
| Sabisz, M; Skladanowski, A; Wesierska-Gadek, J | 1 |
| Goldani, LZ; Pasqualotto, AC; Thiele, KO | 1 |
| Arnould, I; Bellamy, JF; Besnard, F; Blouquit-Laye, S; Buenestado, A; Chapelier, A; Devillier, P; Grassin Delyle, S; Naline, E | 1 |
| Bibian, M; Blayo, AL; El Habnouni, S; Fehrentz, JA; Martinez, J; Moulin, A | 1 |
| Florance, A; Franco, SX; Johnston, S; Maltzman, J; O'Rourke, L; Schwartzberg, LS; Schwarzberg, LS | 1 |
| Arnould, L; Coudert, B; Favier, L; Fumoleau, P; Guiu, S | 1 |
| Anderson, E; Arena, FP; Bacus, S; Cora, EM; Cristofanilli, M; Curcio, E; Kroener, JF; Magill, PJ; Mangalik, A; Rabinowitz, I; Royce, M; Valero, V; Watkins, C | 1 |
| Abdalla, M; Ghorab, MM; Ismail, ZH | 1 |
| Curran, MP | 1 |
| Buchanan, SG; Dekoning, T; Eagleson, B; Essenburg, C; Kang, L; Kaufman, D; Staal, B; Su, Y; Vande Woude, GF; West, R; Zhang, YW | 1 |
| Scheen, AJ | 2 |
| Gerich, J | 1 |
| Amonkar, MM; Johnston, S; Maltzman, J; O'Rourke, L; Sherif, B; Sherrill, B | 2 |
| Canto, M; Ding, P; Dunbar, KB; Eshleman, JR; Feldmann, G; Goff, D; Haffner, MC; Heckrodt, TJ; Hector, A; Holland, SJ; Hong, SM; Karikari, C; Maitra, A; Marimuthu, A; Meeker, AK; Montgomery, EA; Nelkin, BD; Pandey, A; Riggins, GJ; Roa, JC; Singh, R; Wang, JS; Yu, J; Zhang, J | 1 |
| Dobbins, TA; Drew, AK; Harris, CA; Pearson, S; Ward, RL | 1 |
| Schirner, K; Stone, LK; Walker, S | 1 |
| Ashton, S; Barry, ST; Blakey, D; Lewis, CE; Murdoch, C; Tazzyman, S; Wood, P | 1 |
| Sheng, CQ; Wang, SZ; Zhang, WN | 1 |
| Chen, K; Chen, X; Gao, H; Kiesewetter, D; Lang, L; Niu, G; Quan, Q; Sun, X; Yan, Y; Yang, M | 1 |
| Türel, O | 1 |
| Bourdel-Marchasson, I; Dejager, S; Schweizer, A | 1 |
| Beyer, A; Cai, WY; Elledge, R; Fuqua, S; Hilsenbeck, S; Huang, J; Massarweh, S; Rimawi, M; Sexton, K; Tham, YL; Tsimelzon, A; Weiss, H | 1 |
| Cheng, HT; Chu, YH; Shen, MJ; Tseng, MC | 1 |
| Jermendy, G | 2 |
| de Azambuja, E; Metzger-Filho, O | 1 |
| A'Hern, R; Anderson, H; Bliss, J; Dowsett, M; Dunbier, A; Evans, A; Ghazoui, Z; Iskender, A; Johnson, L; Pinhel, I; Robertson, J; Robison, L; Salter, J; Skene, T; Smith, I; Wilcox, M | 1 |
| Alter, M; Chaykovska, L; Fuchs, H; Heiden, S; Hocher, B; Klein, T; Rahnenführer, J; Runge, F; von Websky, K | 1 |
| Armstrong, A; Bagust, A; Blundell, M; Boland, A; Davis, H; Dickson, R; Dundar, Y; Fleeman, N; Moonan, M; Oyee, J; Thorp, N | 1 |
| Moustafa, AH; Osman, NA; Saad, HA | 1 |
| Faldyna, M; Kovaru, F; Kovaru, H; Leva, L; Matiasovic, J; Ondrackova, P | 1 |
| Campbell, J; Gilmore, MS; Singh, AK; Swoboda, JG; Walker, S; Wilkinson, BJ | 1 |
| Avery, MA; Gut, J; Legac, J; Rosenthal, PJ; Shah, F; Sherman, W; Shivakumar, D | 1 |
| Balasubramanian, R; Federico, S; Gao, ZG; Jacobson, KA; Kozma, E; Kumar, TS; Moro, S; Paoletta, S; Phan, K; Spalluto, G | 1 |
| Badve, SS; Carlson, RW; Gomez, HL; O'Neill, A; Sledge, GW; Vidaurre, T | 1 |
| Edwards, KL; Irons, BK; Stapleton, MR; Weis, JM | 1 |
| Ito, Y | 1 |
| Amonkar, MM; Diaz, JR; Forbes, CA; Kleijnen, J; Lykopoulos, K; Rea, DW; Riemsma, R | 1 |
| Gil, C; Lipina, TV; Martinez, A; Palomo, V; Roder, JC | 1 |
| Ishikawa, M; Yamada, Y | 1 |
| Bill, A; Famulok, M; Hannam, JS; Heukamp, LC; König, K; Schmitz, A | 1 |
| Fabbretti, E; Giniatullin, R; Lorenzon, P; Luin, E; Parato, G; Ren, E; Sciancalepore, M | 1 |
| Chen, Z; Li, Z; Liao, M; Lu, S; Niu, X; Shen, L; Shen, S; Yu, Y | 1 |
| Burton, VJ; Butler, M; Parkinson, SJ; Pearson, R; Sanmugalingam, D; Smith, P; Watson, RP; Wilson, T | 1 |
| Hosoya, T; Imai, S; Kuzumaki, N; Morita, H; Nagasawa, A; Narita, M; Okada, Y; Okano, H; Okano, HJ; Suzuki, A; Suzuki, T; Yamamizu, K; Yamashita, JK | 1 |
| Berg, L; Lopper, ME; Sunchu, B; Ward, HE | 1 |
| Bian, M; Deng, XQ; Quan, ZS; Wang, SB; Zheng, Y | 1 |
| Ding, MW; Li, Q; Li, WJ; Liu, DL | 1 |
| Bakris, GL; Flynn, C | 1 |
| Chang, JC; Forero, A; Goetz, MP; Gutierrez, C; Hilsenbeck, SG; Mayer, IA; Nanda, R; Osborne, CK; Pavlick, AC; Rimawi, MF; Rodriguez, AA; Schiff, R; Wang, T | 1 |
| Chaigneau, L; Demarchi, M; Dobi, E; Merrouche, Y; N'guyen, T; Pivot, X; Romieu, G; Salvat, J; Villanueva, C; Vuillemin, AT | 1 |
| Cohen, D | 1 |
| Ardestani, A; Dharmadhikari, G; Kerr-Conte, J; Klein, T; Laue, S; Maedler, K; Pattou, F; Schumann, DM; Shah, P | 1 |
| Charbonnel, B; Dejager, S; Schweizer, A | 1 |
| Malahias, S; Raterink, K; Sigurgeirsson, B; van Rossem, K | 1 |
| Essenburg, C; Kaufman, D; Lewis, S; Staal, B; Vande Woude, GF; Zhang, YW | 1 |
| Li, W; Wu, L; Zhang, C | 1 |
| Candy, PA; Epis, MR; Giles, KM; Goodall, GJ; Kalinowski, FC; Leedman, PJ; Redfern, AD; Stuart, LM; Zhang, PM | 1 |
| Anandappa, G; Turner, NC | 1 |
| Mehta, A; Tripathy, D | 1 |
| Dering, J; Ellis, C; Finn, RS; Florance, A; Johnston, S; Martin, AM; O'Rourke, L; Press, MF | 1 |
| Yaqub, F | 1 |
| Edling, CE; Falasca, M; Ghonaim, R; Maffucci, T; Selvaggi, F | 1 |
| Tibaldi, JM | 1 |
| Artioli, F; Bettelli, S; Bisagni, G; Boni, C; Bottini, A; Cagossi, K; Cavanna, L; Conte, P; Ellis, C; Ficarra, G; Frassoldati, A; Generali, DG; Guarneri, V; Holford, C; Maiorana, A; Nuzzo, S; Piacentini, F; Roncaglia, E; Swaby, R; Tagliafico, E | 1 |
| Banerjee, J; Civan, MM; Gao, ZG; Jacobson, KA; Kambayashi, T; Leung, CT; Li, A | 1 |
| Benjelloun, S; Engels, JW; Lazrek, HB; Ouahrouch, A; Taourirte, M | 1 |
| Athyros, VG; Elisaf, MS; Filippatos, TD | 1 |
| Chandarlapaty, S; Crews, JR; Davidson, NE; Esteva, FJ; Giordano, SH; Gonzalez-Angulo, AM; Kirshner, JJ; Krop, I; Levinson, J; Lin, NU; Modi, S; Patt, DA; Perez, EA; Perlmutter, J; Ramakrishna, N; Temin, S; Winer, EP | 1 |
| Günther, S; Lucas, X | 1 |
| Aguilar, H; Balart, J; Barril, X; Beijersbergen, RL; Bonifaci, N; Bostner, J; Brunet, J; Burnstein, KL; Bustelo, XR; Caizzi, L; Carlson, KE; Clarke, R; Climent, F; Di Croce, L; Esteller, M; Extremera, AI; Figueras, A; Fornander, T; García, N; Garcia-Mata, R; Gil, M; Gómez-Baldó, L; Halonen, P; Islam, A; Jansen, MP; Karlsson, E; Katzenellenbogen, JA; Kiyotani, K; Martrat, G; Mushiroda, T; Nakamura, Y; Nevedomskaya, E; Pérez Tenorio, G; Pujana, MA; Rodríguez-Peña, AB; Rodríguez-Vida, A; Serra-Musach, J; Sgroi, DC; Soler, MT; Stål, O; Urruticoechea, A; Villanueva, A; Vizoso, M; Zembutsu, H; Zwart, W | 1 |
| Cai, Q; Hong, S; Jiang, W; Xu, C; Yu, Y; Zhang, M; Zhang, X | 1 |
| Ballanyi, K; Ciechanski, P; Mosca, EV; Roy, A; Scheibli, EC; Wilson, RJ | 1 |
| Dowsett, M; Gao, Q; Garcia-Murillas, I; López-Knowles, E; Martin, LA; Segal, CV; Smith, I; Turner, NC | 1 |
| Birnbaum, Y; Kodakandla, M; Ling, S; Nanhwan, MK; Nylander, S; Ye, Y | 1 |
| Jin, D; Sakonjo, H; Takai, S | 1 |
| Alefishat, E; Alexander, SP; Ralevic, V | 1 |
| Osborne, CK; Rimawi, MF; Schiff, R | 1 |
| Agdauletova, S; Daiber, A; Hausding, M; Klein, T; Kröller-Schön, S; Li, H; Mader, M; Mikhed, Y; Münzel, T; Oelze, M; Pfeffer, A; Schulz, E; Stamm, P; Steven, S; Sudowe, S; Welschof, P; Zinßius, E | 1 |
| Fujii, N; Kadowaki, N; Kanda, J; Kawabata, H; Oishi, S; Sakamoto, S; Takaori-Kondo, A; Tomosugi, N; Uchiyama, T | 1 |
| Hole, S; Lykkesfeldt, AE; Pedersen, AM; Yde, CW | 1 |
| Chang, CP; Chang, KH; Chen, CT; Cheng, CY; Chou, MC; Huang, CY; Jan, JJ; Sadani, AA; Shia, KS; Song, JS; Tseng, CT; Tsou, LK; Wang, MH; Wong, YC; Wu, CH; Wu, SH; Yeh, CF; Yeh, KC | 1 |
| Ali, A; Anand, R; Culberson, C; Deng, Q; Greene, S; Kim, JH; Levorse, D; Lim, YH; Mullins, D; Parker, EM; Sherborne, B; Stamford, A; Tempest, P; Yu, Y; Zhang, X; Zheng, J; Zhou, W | 1 |
| Harbeck, N | 1 |
| Chen, Y; Ding, J; Geng, M; Huang, M; Shen, A; Shen, YY; Sun, J; Wang, L; Wang, X; Yang, X | 1 |
| Bregni, G; de Braud, F; Di Cosimo, S; Zanardi, E | 1 |
| Basaran, G; Bogaerts, J; Cameron, D; Cufer, T; Debled, M; Dirix, L; Piccart, M; Thery, JC; Tjan-Heijnen, VC; Tryfonidis, K; Van den Weyngaert, D | 1 |
| Beauchemin, C; Lachaine, J; Letarte, N; Mathurin, K; Yelle, L | 1 |
| Antypenko, LM; Fedyunina, NS; Karpenko, OV; Katsev, AM; Kovalenko, SI; Novikov, VP | 1 |
| Abuelizz, HA; Al-Salahi, R; Alotaibi, MA; El Dib, RA; Marzouk, M; Wadi, M | 1 |
| Adamo, B; Cheang, MC; Ellis, C; Gagnon, R; Galván, P; Johnston, S; Muñoz, M; Nuciforo, P; Paré, L; Prat, A; Press, MF; Viladot, M | 1 |
| Ahn, JH; Ahn, SH; Gong, G; Jung, KH; Kang, MJ; Kim, HH; Kim, JE; Kim, SB; Lee, HJ; Moon, DH; Park, JH; Shin, HJ; Son, BH | 1 |
| Basik, M; Clemons, M; Cristofanilli, M; Dreosti, L; Grzeda, L; Hegg, R; Johnston, S; Lausoontornsiri, W; Mann, H; Stuart, M | 1 |
| Chen, CY; Cheng, HT; Chu, YH; Li, HY | 1 |
| Chen, S; Chen, YZ; Ding, C; Hu, G; Jiang, Y; Li, L; Tan, C; Zhang, C; Zhang, W | 1 |
| Bae, E; Chen, CT; Kuan, HH; Shia, KS; Song, JS; Wang, Y; Wu, CH; Wu, KJ; Yeh, KC; Yu, SJ | 1 |
| Kaieda, A; Kanzaki, N; Kori, M; Kuno, H; Mototani, H; Naito, T; Nara, H; Oki, H; Santou, T; Sato, K; Terauchi, J; Uchikawa, O; Yamamoto, Y | 1 |
| Yamamoto, C; Yamamoto, D; Yamamoto, M | 1 |
| Banna, G; Berardi, R; Bisagni, G; Cagossi, K; Cavanna, L; Conte, P; Dieci, MV; Ficarra, G; Frassoldati, A; Generali, D; Goubar, A; Griguolo, G; Guarneri, V; Michelotti, A; Piacentini, F; Puglisi, F | 1 |
| Ishikawa, T; Nakamura, M; Nishiyama, R; Saito, SY; Todoroki, K; Toyo'oka, T; Yamaguchi, M | 1 |
| Cao, Q; Gong, GH; Quan, ZS; Wang, XZ; Zhang, HJ | 1 |
| Bolin, S; Borgenvik, A; Bradner, JE; Cho, YJ; Persson, CU; Qi, J; Sundström, A; Swartling, FJ; Weishaupt, H; Weiss, WA | 1 |
| Bode, A; Grubbs, CJ; Juliana, MM; Lubet, RA; Moeinpour, F; Steele, VE | 1 |
| Bao, X; Fan, Z; Shi, J | 1 |
| Butterton, JR; Cho, CR; de Haes, JIU; Drexel, M; Hulskotte, EGJ; Hussaini, A; Iwamoto, M; Jordan, HR; Kantesaria, BS; Liu, F; Macha, S; Marshall, WL; McCrea, JB; Menzel, K; Tsai, C; van Schanke, A | 1 |
| Gatto, C; Tiwari, KB; Walker, S; Wilkinson, BJ | 1 |
| Dubey, AK; Singla, RK; Srivastava, V | 1 |
| Aertgeerts, K; Appleton, B; Breitenbucher, JG; Gomez, L; Ly, K; Marrone, T; Massari, ME; Metz, M; Sebring, K; Selfridge, B; Sinko, W; Truong, R; Vernier, W; Xu, R; Yan, Y | 1 |
| Karasawa, T; Kumagai, N; Oriez, R; Shibasaki, M | 1 |
| Anjum, R; Barry, E; Bhavsar, D; Boyd, S; Brown, C; Campbell, A; Goldberg, K; Grondine, M; Guichard, S; Hardy, CJ; Hunt, T; Jones, RDO; Kettle, JG; Li, X; Moleva, O; Ogg, D; Overman, RC; Packer, MJ; Pearson, S; Schimpl, M; Shao, W; Smith, A; Smith, JM; Stead, D; Stokes, S; Tucker, M; Ye, Y | 1 |
| Dang Thi, TA; Dinh, TV; Hoang Thi, P; Le Duc, T; Le Thi, TA; Le-Nhat-Thuy, G; Nguyen Quang, H; Nguyen Thanh, P; Nguyen Thi, N; Nguyen, HT; Nguyen, TV; Pham-The, H | 1 |
| Hino, K; Horigome, K; Ikeya, M; Komura, S; Nagata, S; Nishio, M; Ohta, A; Okanishi, Y; Toguchida, J; Yamada, Y; Zhao, C | 1 |
| Ballatore, C; Brunden, KR; Cornec, AS; James, MJ; Koivula, P; Lee, VM; Oukoloff, K; Smith, AB; Trojanowski, JQ; Yao, Y; Zhang, B | 1 |
| Brocato, RL; Hooper, JW | 1 |
| Abuelizz, HA; Ahmad, R; Al-Salahi, R; Anouar, EH; Azman, NIIN; Marzouk, M | 1 |
| Bridges, TM; Chang, S; Conn, PJ; Engers, DW; Engers, JL; Lindsley, CW; Long, MF; Luscombe, VB; Niswender, CM; Rodriguez, AL; Temple, KJ; Watson, KJ | 1 |
| Anjum, R; Banks, E; Barry, E; Bhavsar, D; Brown, C; Grondine, M; Guichard, SM; Jones, RDO; Kettle, JG; Pilla Reddy, V; Shao, W; Smith, A | 1 |
| Caprioli, RM; Laut, CL; Metzger, AL; Perry, WJ; Skaar, EP; Stauff, DL; Walker, S; Weiss, A | 1 |
| Dang Thi, TA; Le-Nhat-Thuy, G; Nguyen Hoang, S; Nguyen Thi, H; Nguyen Thi, N; Nguyen Thi, TH; Nguyen, TV; Pham-The, H | 1 |
| Ahmed, HEA; Almehmadi, MA; Aouad, MR; Ihmaid, S; Omar, AM; Rezki, N; Shehata, AM | 1 |
| Kirby, JE; Zulauf, KE | 1 |
| Fülöp, F; Haukka, M; Palkó, M; Said, AI | 1 |
| Chen, Y; Deng, H; Du, W; Gao, H; He, Q; Lan, T; Li, T; Liu, Y; Meng, X; Rao, Y; Shao, X; Sun, X; Tao, X; Tong, Y; Wang, L; Wang, W; Wu, Y; Xu, A; Yang, B; Ying, M; Zhong, T | 1 |
| Jang, HS; Kerkvliet, NI; Kolluri, SK; Liefwalker, DF; O'Donnell, EF | 1 |
| Bernardes, ES; Carvalho, I; da Silva, G; de Andrade, P; Kawano, DF; Leopoldino, AM; Mantoani, SP; Nascimento, S; Nunes, PSG | 1 |
| Abulkhair, HS; Al-Karmalawy, AA; Bayoumi, AH; El-Shershaby, MH; El-Zoghbi, MS; Ghiaty, A; Husseiny, EM | 1 |
| Abuelizz, HA; Al-Salahi, R | 1 |
| Beesley, J; Gause, WC; Haskó, G; Lovászi, M; Németh, ZH; Pacher, P | 1 |
| Alesawy, MS; Eissa, IH; El-Adl, K; Ibrahim, MK | 2 |
| Alcívar-León, CD; Cadena-Cruz, JE; Heredia-Moya, J; Zurita, DA | 1 |
| Baumann, U; Bertrand, J; Flegel, J; Gihring, A; Halver, J; Ketzel, J; Knippschild, U; Lohmann, S; Müller, E; Peifer, C; Pichlo, C; Rastegar, S; Riege, D; Roth, A; Schade, D; Sievers, S; Takamiya, M; Waldmann, H; Weber, S; Wesseler, F | 1 |
| Jiang, Y; Li, J; Xiao, T; Yang, B; Zhang, S | 1 |
| Andrei, G; Camps, A; Gawron, K; Graus, M; Głowacka, IE; Piotrowska, DG; Schols, D; Snoeck, R; Vanhulle, E; Vermeire, K | 1 |
38 review(s) available for quinazolines and triazoles
| Article | Year |
|---|---|
The adenosine A3 receptor and its ligands.
Topics: Adenosine; Amino Acid Sequence; Animals; Cardiovascular Diseases; Cloning, Molecular; Flavonoids; Humans; Immune System Diseases; Lung Diseases; Models, Animal; Molecular Sequence Data; Protein Binding; Pyrans; Pyridines; Quinazolines; Receptors, Purinergic; Sequence Alignment; Species Specificity; Triazoles; Xanthines | 2001 |
Specific treatment of Chagas disease: current status and new developments.
Topics: Chagas Disease; Cysteine Proteinase Inhibitors; Humans; Quinazolines; Triazoles | 2001 |
Endocrine treatment options for advanced breast cancer--the role of fulvestrant.
Topics: Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Estradiol; Estrogen Antagonists; Female; Fulvestrant; Gefitinib; Humans; Nitriles; Postmenopause; Quinazolines; Tamoxifen; Treatment Outcome; Triazoles | 2005 |
Innovations in antineoplastic therapy.
Topics: Adjuvants, Immunologic; Alemtuzumab; Aminoglycosides; Anastrozole; Androstadienes; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Neoplasm; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Benzamides; Bile; Boronic Acids; Bortezomib; Capecitabine; Cetuximab; Decanoic Acids; Deoxycytidine; Docetaxel; Drug Approval; Estradiol; Fluorouracil; Fulvestrant; Gefitinib; Gemtuzumab; Humans; Imatinib Mesylate; Letrozole; Leuprolide; Nitriles; Oligopeptides; Organoplatinum Compounds; Oxaliplatin; Oxides; Piperazines; Polyesters; Pyrazines; Pyrimidines; Quinazolines; Taxoids; Thionucleotides; Tissue Extracts; Triazoles; United States; United States Food and Drug Administration; Vidarabine Phosphate | 2005 |
A2B adenosine receptor antagonists: recent developments.
Topics: Adenosine A2 Receptor Antagonists; Amino Acid Sequence; Animals; Anti-Asthmatic Agents; Anti-Inflammatory Agents; Asthma; Binding Sites; Drug Design; Humans; Molecular Sequence Data; Quinazolines; Triazoles; Xanthines | 2005 |
Progress in the pursuit of therapeutic adenosine receptor antagonists.
Topics: Adenosine A1 Receptor Antagonists; Adenosine A2 Receptor Antagonists; Adenosine A3 Receptor Antagonists; Amino Acid Sequence; Animals; Flavonoids; Heterocyclic Compounds; Humans; Purinergic P1 Receptor Antagonists; Quantitative Structure-Activity Relationship; Quinazolines; Receptor, Adenosine A2B; Triazoles; Xanthines | 2006 |
New and emerging treatments for fungal infections.
Topics: Animals; Antifungal Agents; Drug Resistance, Fungal; Humans; Mycoses; Quinazolines; Stereoisomerism; Triazoles | 2008 |
Lapatinib plus letrozole for postmenopausal patients with advanced HER2(+)/HR(+) breast cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine; Drug Resistance, Neoplasm; ErbB Receptors; Female; Fluorouracil; Humans; Lapatinib; Letrozole; Neoplasms, Hormone-Dependent; Nitriles; Postmenopause; Quinazolines; Receptor, ErbB-2; Trastuzumab; Triazoles | 2009 |
Novel triazole antifungal drugs: focus on isavuconazole, ravuconazole and albaconazole.
Topics: Animals; Antifungal Agents; Clinical Trials as Topic; Drug Resistance, Fungal; Fungi; Humans; Microbial Sensitivity Tests; Mycoses; Nitriles; Pyridines; Quinazolines; Thiazoles; Triazoles | 2010 |
Synthesis of 3,4,5-trisubstituted-1,2,4-triazoles.
Topics: Amides; Hydrazones; Oxadiazoles; Oxazolone; Quinazolines; Thioamides; Triazoles | 2010 |
[Management of metastatic HER2-positive breast cancer: present and future].
Topics: Anastrozole; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Benzoquinones; Bevacizumab; Brain Neoplasms; Breast Neoplasms; Disease Progression; Female; Heart; Humans; Lactams, Macrocyclic; Lapatinib; Letrozole; Neoplasm Proteins; Nitriles; Quinazolines; Quinolines; Receptor, ErbB-2; Trastuzumab; Triazoles | 2010 |
Lapatinib: in postmenopausal women with hormone receptor-positive, HER2-positive metastatic breast cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; ErbB Receptors; Female; Humans; Lapatinib; Letrozole; Middle Aged; Neoplasm Metastasis; Nitriles; Postmenopause; Protein Kinase Inhibitors; Quinazolines; Receptor, ErbB-2; Triazoles | 2010 |
Dipeptidylpeptidase-4 inhibitors (gliptins): focus on drug-drug interactions.
Topics: Adamantane; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Drug Interactions; Humans; Linagliptin; Nitriles; Piperidines; Purines; Pyrazines; Pyrrolidines; Quinazolines; Sitagliptin Phosphate; Triazoles; Uracil; Vildagliptin | 2010 |
DPP-4 inhibitors: what may be the clinical differentiators?
Topics: Adamantane; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Energy Intake; Gastric Emptying; Glucagon-Like Peptide 1; Glycated Hemoglobin; Humans; Hyperglycemia; Hypoglycemic Agents; Incretins; Intestinal Mucosa; Linagliptin; Neurons; Nitriles; Piperidines; Purines; Pyrazines; Pyrrolidines; Quinazolines; Sitagliptin Phosphate; Triazoles; Uracil; Vildagliptin | 2010 |
The efficacy of HER2-targeted agents in metastatic breast cancer: a meta-analysis.
Topics: Anastrozole; Anthracyclines; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Clinical Trials as Topic; Deoxycytidine; Female; Fluorouracil; Humans; Lapatinib; Letrozole; Neoplasm Metastasis; Nitriles; Quinazolines; Receptor, ErbB-2; Taxoids; Trastuzumab; Treatment Outcome; Triazoles | 2011 |
[Recent advances in the study of new antifungal lead compounds].
Topics: Antifungal Agents; Fungi; Heterocyclic Compounds; Humans; Lipopeptides; Molecular Structure; Mycoses; Nitriles; Plant Extracts; Plants, Medicinal; Pyridines; Quinazolines; Quinones; Structure-Activity Relationship; Thiazoles; Triazoles | 2010 |
Newer antifungal agents.
Topics: Animals; Antifungal Agents; Aspergillosis; Aspergillus; Candida; Candidiasis, Invasive; Child; Clinical Trials as Topic; Half-Life; Humans; Lipopeptides; Nitriles; Pyridines; Quinazolines; Thiazoles; Triazoles | 2011 |
Incretin therapies in the management of elderly patients with type 2 diabetes mellitus.
Topics: Adamantane; Age Factors; Aged; Aging; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Exenatide; Female; Glucagon-Like Peptide 1; Humans; Hypoglycemic Agents; Incretins; Linagliptin; Liraglutide; Male; Middle Aged; Nitriles; Peptides; Piperidines; Purines; Pyrazines; Pyrrolidines; Quinazolines; Sitagliptin Phosphate; Treatment Outcome; Triazoles; Uracil; Venoms; Vildagliptin | 2011 |
[Dipeptidyl-peptidase-4 inhibitors (gliptins): a new class of oral antidiabetic drugs].
Topics: Adamantane; Animals; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Drug Administration Schedule; Drug Therapy, Combination; Humans; Hypoglycemic Agents; Incretins; Linagliptin; Metformin; Nitriles; Purines; Pyrazines; Pyrrolidines; Quinazolines; Sitagliptin Phosphate; Tablets; Treatment Outcome; Triazoles; Vildagliptin | 2011 |
[Incretin-based therapy for treating patients with type 2 diabetes].
Topics: Adamantane; Body Mass Index; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Drug Approval; Drug Therapy, Combination; Exenatide; Gliclazide; Glucagon-Like Peptide 1; Glucagon-Like Peptide-1 Receptor; Glycated Hemoglobin; Humans; Hungary; Hypoglycemic Agents; Incretins; Linagliptin; Liraglutide; Metformin; Nitriles; Peptides; Pioglitazone; Purines; Pyrazines; Pyrrolidines; Quinazolines; Receptors, Glucagon; Sitagliptin Phosphate; Sulfonylurea Compounds; Thiazolidinediones; Triazoles; Venoms; Vildagliptin | 2011 |
Lapatinib and trastuzumab in combination with an aromatase inhibitor for the first-line treatment of metastatic hormone receptor-positive breast cancer which over-expresses human epidermal growth factor 2 (HER2): a systematic review and economic analysis.
Topics: Anastrozole; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials as Topic; Cost-Benefit Analysis; Disease-Free Survival; Female; Humans; Lapatinib; Letrozole; Nitriles; Quinazolines; Receptor, ErbB-2; Trastuzumab; Triazoles | 2011 |
DPP-4 inhibitors in the management of type 2 diabetes: a critical review of head-to-head trials.
Topics: Adamantane; Clinical Trials as Topic; Cost-Benefit Analysis; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Drug Therapy, Combination; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Linagliptin; Male; Metformin; Nitriles; Piperidines; Purines; Pyrazines; Pyrrolidines; Quinazolines; Sitagliptin Phosphate; Triazoles; Uracil; Vildagliptin; Weight Gain | 2012 |
An update in incretin-based therapy: a focus on dipeptidyl peptidase--4 inhibitors.
Topics: Adamantane; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Drug Interactions; Female; Glucagon-Like Peptide 1; Humans; Linagliptin; Male; Nitriles; Piperidines; Purines; Pyrazines; Pyrrolidines; Quinazolines; Sitagliptin Phosphate; Treatment Outcome; Triazoles; Uracil; Vildagliptin | 2012 |
[Progress of molecularly targeted therapy for breast cancer].
Topics: Ado-Trastuzumab Emtansine; Antibodies, Monoclonal, Humanized; Breast Neoplasms; Denosumab; Drug Design; Drug Therapy, Combination; Everolimus; Humans; Lapatinib; Letrozole; Maytansine; Molecular Targeted Therapy; Nitriles; Quinazolines; Receptor, ErbB-2; Sirolimus; Tamoxifen; Trastuzumab; Triazoles | 2012 |
Systematic review of lapatinib in combination with letrozole compared with other first-line treatments for hormone receptor positive(HR+) and HER2+ advanced or metastatic breast cancer(MBC).
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma; Disease Progression; Female; Humans; Lapatinib; Letrozole; Neoadjuvant Therapy; Neoplasm Metastasis; Nitriles; Quinazolines; Receptor, ErbB-2; Receptors, Cytoplasmic and Nuclear; Triazoles | 2012 |
Noninsulin glucose-lowering agents for the treatment of patients on dialysis.
Topics: Adamantane; Biguanides; Diabetic Nephropathies; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Disease Progression; Glucagon-Like Peptides; Glycoside Hydrolase Inhibitors; Humans; Hypoglycemic Agents; Linagliptin; Meglumine; Metformin; Nitriles; Piperidines; Purines; Pyrazines; Pyrrolidines; Quinazolines; Renal Dialysis; Renal Insufficiency, Chronic; Sitagliptin Phosphate; Sulfonylurea Compounds; Thiazolidinediones; Treatment Outcome; Triazoles; Uracil; Vildagliptin | 2013 |
Combination therapy with DPP-4 inhibitors and insulin in patients with type 2 diabetes mellitus: what is the evidence?
Topics: Adamantane; Body Weight; Diabetes Complications; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Disease Progression; Drug Therapy, Combination; Humans; Hypoglycemia; Hypoglycemic Agents; Insulin; Linagliptin; Nitriles; Piperidines; Purines; Pyrazines; Pyrrolidines; Quinazolines; Renal Insufficiency, Chronic; Sitagliptin Phosphate; Triazoles; Uracil; Vildagliptin | 2013 |
Targeting receptor tyrosine kinases in HER2-negative breast cancer.
Topics: Anastrozole; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Clinical Trials, Phase II as Topic; Disease-Free Survival; Drug Administration Schedule; ErbB Receptors; Female; Gefitinib; Gene Expression Regulation, Neoplastic; Humans; Molecular Targeted Therapy; Nitriles; Prospective Studies; Protein Kinase Inhibitors; Quinazolines; Randomized Controlled Trials as Topic; Receptor Protein-Tyrosine Kinases; Receptor, ErbB-2; Receptor, ErbB-3; Signal Transduction; Treatment Outcome; Triazoles; Up-Regulation | 2013 |
Co-targeting estrogen receptor and HER2 pathways in breast cancer.
Topics: Anastrozole; Androstadienes; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms; Estradiol; Everolimus; Female; Fulvestrant; Gefitinib; Humans; Lapatinib; Letrozole; Molecular Targeted Therapy; Nitriles; Quinazolines; Receptor, ErbB-2; Receptors, Estrogen; Signal Transduction; Sirolimus; Tamoxifen; Trastuzumab; Triazoles | 2014 |
Incorporating incretin-based therapies into clinical practice for patients with type 2 diabetes.
Topics: Adamantane; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Exenatide; Glucagon-Like Peptide 1; Glucagon-Like Peptide-1 Receptor; Humans; Hypoglycemic Agents; Linagliptin; Liraglutide; Peptides; Piperidines; Purines; Pyrazines; Quinazolines; Receptors, Glucagon; Sitagliptin Phosphate; Treatment Outcome; Triazoles; Uracil; Venoms; Weight Loss | 2014 |
The pharmacokinetic considerations and adverse effects of DPP-4 inhibitors [corrected].
Topics: Adamantane; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Drug Interactions; Humans; Linagliptin; Nitriles; Piperidines; Piperidones; Purines; Pyrazines; Pyrazoles; Pyrimidines; Pyrrolidines; Quinazolines; Sitagliptin Phosphate; Thiazolidines; Triazoles; Uracil; Vildagliptin | 2014 |
Systemic therapy for patients with advanced human epidermal growth factor receptor 2-positive breast cancer: American Society of Clinical Oncology clinical practice guideline.
Topics: Ado-Trastuzumab Emtansine; Anastrozole; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Clinical Trials as Topic; Comorbidity; Docetaxel; Drug Administration Schedule; Evidence-Based Medicine; Female; Health Status Disparities; Healthcare Disparities; Humans; Lapatinib; Letrozole; Maytansine; Molecular Targeted Therapy; Nitriles; Quinazolines; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Societies, Medical; Taxoids; Trastuzumab; Treatment Outcome; Triazoles; United States | 2014 |
Targeting HER2 for the treatment of breast cancer.
Topics: Anastrozole; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms; Carcinoma; Female; Humans; Lapatinib; Nitriles; Quinazolines; Receptor, ErbB-2; Receptors, Estrogen; Trastuzumab; Triazoles | 2015 |
Better Together: Targeted Combination Therapies in Breast Cancer.
Topics: Androstadienes; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Drug Resistance, Neoplasm; Everolimus; Female; Humans; Lapatinib; Letrozole; Molecular Targeted Therapy; Nitriles; Piperazines; Protein Kinase Inhibitors; Pyridines; Quinazolines; Receptor, ErbB-2; Trastuzumab; Triazoles | 2015 |
Emerging Virulence, Drug Resistance and Future Anti-fungal Drugs for Candida Pathogens.
Topics: Amidines; Antifungal Agents; Candida; Drug Resistance, Fungal; Glycosides; Microbial Sensitivity Tests; Pyridines; Quinazolines; Tetrazoles; Triazoles; Triterpenes; Virulence | 2018 |
Progress on the Prevention and Treatment of Hantavirus Disease.
Topics: Adrenal Cortex Hormones; Amides; Animals; Antiviral Agents; Clinical Trials as Topic; Hantavirus Infections; Hantavirus Pulmonary Syndrome; Hemorrhagic Fever with Renal Syndrome; Humans; Immunotherapy; Lactoferrin; Models, Animal; Nucleosides; Orthohantavirus; Piperidines; Pyrazines; Quinazolines; Recombinant Proteins; Ribavirin; Triazoles; Vaccines, Synthetic; Viral Vaccines | 2019 |
An overview of triazoloquinazolines: Pharmacological significance and recent developments.
Topics: Analgesics; Anti-Infective Agents; Antimalarials; Antineoplastic Agents; Drug Development; Humans; Quinazolines; Triazoles | 2021 |
Diaza-1,3-butadienes as Useful Intermediate in Heterocycles Synthesis.
Topics: Butadienes; Hydrazones; Imidazolidines; Imidazolines; Imines; Indoles; Isoquinolines; Lactams; Pyrazoles; Pyrimidinones; Quinazolines; Triazoles | 2022 |
21 trial(s) available for quinazolines and triazoles
| Article | Year |
|---|---|
Preoperative gefitinib versus gefitinib and anastrozole in postmenopausal patients with oestrogen-receptor positive and epidermal-growth-factor-receptor-positive primary breast cancer: a double-blind placebo-controlled phase II randomised trial.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Double-Blind Method; England; ErbB Receptors; Female; Gefitinib; Humans; Ki-67 Antigen; Middle Aged; Neoadjuvant Therapy; Neoplasms, Hormone-Dependent; Nitriles; Postmenopause; Protein Kinase Inhibitors; Quinazolines; Receptors, Estrogen; Treatment Outcome; Triazoles; Ultrasonography | 2005 |
A phase II placebo-controlled trial of neoadjuvant anastrozole alone or with gefitinib in early breast cancer.
Topics: Aged; Anastrozole; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; ErbB Receptors; Estradiol; Female; Gefitinib; Humans; Ki-67 Antigen; Mastectomy; Nitriles; Quinazolines; Receptor, ErbB-2; Receptors, Progesterone; Triazoles | 2007 |
Letrozole versus letrozole plus Lapatinib (GW572016) in hormone-sensitive, HER2-negative operable breast cancer: a double-blind, randomized, phase II study with biomarker evaluation (EGF109077-LAP107692/LETLOB).
Topics: Antineoplastic Agents; Breast Neoplasms; Double-Blind Method; Female; Genes, erbB-2; Humans; Lapatinib; Letrozole; Middle Aged; Neoplasm Staging; Nitriles; Postmenopause; Quinazolines; Treatment Outcome; Triazoles | 2008 |
A phase I and pharmacokinetic study of lapatinib in combination with letrozole in patients with advanced cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Breast Neoplasms; Female; Humans; Lapatinib; Letrozole; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Nitriles; Ovarian Neoplasms; Quinazolines; Triazoles | 2008 |
Lapatinib combined with letrozole versus letrozole and placebo as first-line therapy for postmenopausal hormone receptor-positive metastatic breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Carcinoma; Disease-Free Survival; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Female; Humans; Kaplan-Meier Estimate; Lapatinib; Letrozole; Maximum Tolerated Dose; Middle Aged; Neoplasm Invasiveness; Neoplasm Staging; Nitriles; Postmenopause; Prognosis; Proportional Hazards Models; Quinazolines; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Risk Assessment; Survival Analysis; Treatment Outcome; Triazoles | 2009 |
Lapatinib plus letrozole as first-line therapy for HER-2+ hormone receptor-positive metastatic breast cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Disease-Free Survival; Double-Blind Method; Drug Synergism; Female; Humans; Lapatinib; Letrozole; Middle Aged; Nitriles; Placebos; Postmenopause; Quinazolines; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Treatment Outcome; Triazoles | 2010 |
Phase II, randomized trial to compare anastrozole combined with gefitinib or placebo in postmenopausal women with hormone receptor-positive metastatic breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Anastrozole; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Double-Blind Method; ErbB Receptors; Female; Gefitinib; Humans; Lymphatic Metastasis; Middle Aged; Neoplasm Metastasis; Neoplasms, Hormone-Dependent; Nitriles; Postmenopause; Prospective Studies; Quinazolines; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Survival Rate; Tissue Distribution; Treatment Outcome; Triazoles | 2010 |
Quality of life in hormone receptor-positive HER-2+ metastatic breast cancer patients during treatment with letrozole alone or in combination with lapatinib.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Disease-Free Survival; Double-Blind Method; Female; Humans; Lapatinib; Letrozole; Nitriles; Quality of Life; Quinazolines; Receptor, ErbB-2; Triazoles | 2010 |
A phase II neoadjuvant trial of anastrozole, fulvestrant, and gefitinib in patients with newly diagnosed estrogen receptor positive breast cancer.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Breast Neoplasms, Male; Cell Cycle; Cyclin D1; Estradiol; Female; Fulvestrant; Gefitinib; Humans; Ki-67 Antigen; Male; Mitogen-Activated Protein Kinases; Neoadjuvant Therapy; Nitriles; Oncogene Protein v-akt; Proto-Oncogene Proteins; Quinazolines; Receptors, Estrogen; Receptors, Progesterone; Triazoles | 2011 |
Quality-adjusted survival analysis of first-line treatment of hormone-receptor-positive HER2+ metastatic breast cancer with letrozole alone or in combination with lapatinib.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Disease-Free Survival; Double-Blind Method; Female; Humans; Lapatinib; Letrozole; Nitriles; Quinazolines; Receptor, ErbB-2; Survival Rate; Triazoles | 2011 |
A randomized trial of combination anastrozole plus gefitinib and of combination fulvestrant plus gefitinib in the treatment of postmenopausal women with hormone receptor positive metastatic breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Anastrozole; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Estradiol; Female; Fulvestrant; Gefitinib; Humans; Middle Aged; Neoplasm Metastasis; Nitriles; Quinazolines; Receptors, Estrogen; Receptors, Progesterone; Survival Analysis; Treatment Outcome; Triazoles | 2012 |
Impairment of adenosine A3 receptor activity disrupts neutrophil migratory capacity and impacts innate immune function in vivo.
Topics: Adenosine; Adenosine A3 Receptor Agonists; Adenosine A3 Receptor Antagonists; Animals; Chemotaxis; Colitis; Dextran Sulfate; Disease Models, Animal; Humans; Immunity, Innate; Inflammation; Mice; Mice, Knockout; Neutrophils; Quinazolines; Receptor, Adenosine A3; Triazoles; Up-Regulation | 2012 |
Multicenter phase II study of neoadjuvant lapatinib and trastuzumab with hormonal therapy and without chemotherapy in patients with human epidermal growth factor receptor 2-overexpressing breast cancer: TBCRC 006.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Drug Administration Schedule; Female; Humans; Lapatinib; Letrozole; Lymphatic Metastasis; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Nitriles; Quinazolines; Receptor, ErbB-2; Receptors, Estrogen; Trastuzumab; Treatment Outcome; Triazoles; Up-Regulation | 2013 |
Phase II study assessing lapatinib added to letrozole in patients with progressive disease under aromatase inhibitor in metastatic breast cancer-Study BES 06.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms; Cohort Studies; Drug Resistance, Neoplasm; ErbB Receptors; Female; Humans; Lapatinib; Letrozole; Middle Aged; Neoplasm Grading; Nitriles; Quinazolines; Receptor, ErbB-2; Treatment Outcome; Triazoles | 2013 |
A phase II, randomized, double-blind, placebo-controlled, parallel group, dose-ranging study to investigate the efficacy and safety of 4 dose regimens of oral albaconazole in patients with distal subungual onychomycosis.
Topics: Administration, Oral; Adult; Aged; Antifungal Agents; Double-Blind Method; Female; Foot Dermatoses; Humans; Male; Middle Aged; Onychomycosis; Quinazolines; Time Factors; Treatment Outcome; Triazoles; Young Adult | 2013 |
Double-blind, placebo-controlled, multicenter, randomized, phase IIb neoadjuvant study of letrozole-lapatinib in postmenopausal hormone receptor-positive, human epidermal growth factor receptor 2-negative, operable breast cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Class I Phosphatidylinositol 3-Kinases; Double-Blind Method; Female; Humans; Ki-67 Antigen; Lapatinib; Letrozole; Middle Aged; Mutation; Neoadjuvant Therapy; Nitriles; Phosphatidylinositol 3-Kinases; Phosphorylation; Postmenopause; Proto-Oncogene Proteins c-akt; Quinazolines; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Triazoles | 2014 |
Relationship of PIK3CA mutation and pathway activity with antiproliferative response to aromatase inhibition.
Topics: Aged; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Biomarkers, Tumor; Breast Neoplasms; Cell Proliferation; Class I Phosphatidylinositol 3-Kinases; ErbB Receptors; Female; Gefitinib; Humans; Ki-67 Antigen; Mechanistic Target of Rapamycin Complex 1; Multiprotein Complexes; Nitriles; Phosphatidylinositol 3-Kinases; Prognosis; Protein Kinase Inhibitors; Quinazolines; Receptors, Estrogen; Receptors, Progesterone; TOR Serine-Threonine Kinases; Triazoles | 2014 |
A European Organisation for Research and Treatment of Cancer randomized, double-blind, placebo-controlled, multicentre phase II trial of anastrozole in combination with gefitinib or placebo in hormone receptor-positive advanced breast cancer (NCT00066378)
Topics: Adult; Aged; Aged, 80 and over; Anastrozole; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Double-Blind Method; Early Termination of Clinical Trials; Female; Gefitinib; Humans; Middle Aged; Nitriles; Quinazolines; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Treatment Outcome; Triazoles | 2016 |
Phase II trial of neoadjuvant letrozole and lapatinib in Asian postmenopausal women with estrogen receptor (ER) and human epidermal growth factor receptor 2 (HER2)-positive breast cancer [Neo-ALL-IN]: Highlighting the TILs, ER expressional change after ne
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Asian People; Biomarkers, Tumor; Breast Neoplasms; Combined Modality Therapy; Female; Humans; Lapatinib; Letrozole; Lymphocyte Count; Lymphocytes, Tumor-Infiltrating; Mastectomy; Middle Aged; Neoadjuvant Therapy; Nitriles; Positron-Emission Tomography; Postmenopause; Quinazolines; Receptor, ErbB-2; Receptors, Estrogen; Triazoles | 2016 |
Inhibition of EGFR, HER2, and HER3 signaling with AZD8931 in combination with anastrozole as an anticancer approach: Phase II randomized study in women with endocrine-therapy-naïve advanced breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Anastrozole; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Combined Modality Therapy; ErbB Receptors; Female; Humans; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Nitriles; Quinazolines; Receptor, ErbB-2; Receptor, ErbB-3; Retreatment; Signal Transduction; Treatment Outcome; Triazoles | 2016 |
Pharmacokinetics and Tolerability of Letermovir Coadministered With Azole Antifungals (Posaconazole or Voriconazole) in Healthy Subjects.
Topics: Acetates; Administration, Oral; Adult; Antifungal Agents; Antiviral Agents; Area Under Curve; Drug Combinations; Drug Interactions; Female; Healthy Volunteers; Humans; Middle Aged; Quinazolines; Triazoles; Voriconazole | 2018 |
256 other study(ies) available for quinazolines and triazoles
| Article | Year |
|---|---|
[Synthesis of compounds with aminoguanidine structure. 4. 4-Aryl-s-triazolo[4,3-a].(5)quinazoline].
Topics: Methods; Quinazolines; Triazoles | 1978 |
[Synthesis of compounds with aminoguanidine structure. 5. 1-Methyl-4-aryl-s-triazolo[4,3-a](5)quinazolone, 1,4-diaryl-s-triazolo[4,3-a](5)quinazolone and 4-aryltetrazolo[1,5-a](5)quinazolone].
Topics: Chemical Phenomena; Chemistry; Methods; Oxidation-Reduction; Quinazolines; Triazoles | 1978 |
Excitatory transmitter amino acid release from the ischemic rat cerebral cortex: effects of adenosine receptor agonists and antagonists.
Topics: Adenosine; Adenosine-5'-(N-ethylcarboxamide); Animals; Aspartic Acid; Brain Ischemia; Cerebral Cortex; Glutamates; Glutamic Acid; Male; Neurotransmitter Agents; Purinergic Antagonists; Quinazolines; Rats; Rats, Inbred Strains; Receptors, Purinergic; Triazoles; Xanthines | 1992 |
Selective adenosine-2 agonist produces both direct and reflex tachycardia in normotensive rats.
Topics: Adenosine; Adrenergic beta-Antagonists; Animals; Blood Pressure; Dose-Response Relationship, Drug; Ganglia, Sympathetic; Heart Rate; Male; Purinergic Antagonists; Quinazolines; Rats; Rats, Inbred Strains; Receptors, Purinergic; Sympathetic Nervous System; Triazoles; Vascular Resistance | 1992 |
Evidence that the increase in striatal c-fos following acute high-dose caffeine is not due to direct interaction with striatal adenosine receptors.
Topics: Adenosine; Animals; Caffeine; Corpus Striatum; Dose-Response Relationship, Drug; Genes, fos; Purinergic Antagonists; Quinazolines; Rats; RNA, Messenger; Triazoles; Xanthines | 1992 |
Influence of the adenosine receptor antagonist, CGS 15943A, on renal function after reconstruction of chronic renal artery stenosis in the dog.
Topics: Adenosine; Animals; Constriction, Pathologic; Creatinine; Dogs; Hemodynamics; Kidney; Purinergic Antagonists; Quinazolines; Renal Artery; Renal Circulation; Triazoles | 1992 |
Behavioural effects of selective A2 adenosine receptor antagonists, CGS 21197 and CGS 22706, in mice.
Topics: Analysis of Variance; Animals; Behavior, Animal; Male; Mice; Mice, Inbred Strains; Motor Activity; Purinergic Antagonists; Pyrimidines; Quinazolines; Triazoles | 1991 |
Synthesis and benzodiazepine binding activity of a series of novel [1,2,4]triazolo[1,5-c]quinazolin-5(6H)-ones.
Topics: Animals; Binding, Competitive; Brain; Diazepam; Flunitrazepam; Indicators and Reagents; Molecular Structure; Quinazolines; Rats; Receptors, GABA-A; Structure-Activity Relationship; Triazoles | 1991 |
Subtypes of adenosine receptors in the brainstem mediate opposite blood pressure responses.
Topics: Adenosine; Animals; Antihypertensive Agents; Blood Pressure; Brain Stem; Dose-Response Relationship, Drug; Male; Phenethylamines; Quinazolines; Rats; Rats, Inbred Strains; Receptors, Purinergic; Triazoles; Xanthines | 1991 |
Do adenosinergic substrates mediate methylxanthine effects upon reinforcement thresholds for electrical brain stimulation in the rat?
Topics: Adenosine; Adenosine-5'-(N-ethylcarboxamide); Animals; Brain; Carbolines; Chlordiazepoxide; Electric Stimulation; Hypothalamic Area, Lateral; Male; Midazolam; Phenylisopropyladenosine; Quinazolines; Rats; Rats, Inbred Strains; Receptors, Purinergic; Reinforcement, Psychology; Self Stimulation; Sensory Thresholds; Theophylline; Triazoles | 1991 |
CGS 15943, a nonxanthine adenosine receptor antagonist: effects on locomotor activity of nontolerant and caffeine-tolerant rats.
Topics: Adenosine; Adenosine-5'-(N-ethylcarboxamide); Animals; Caffeine; Dose-Response Relationship, Drug; Drug Tolerance; Male; Motor Activity; Quinazolines; Rats; Rats, Inbred Strains; Triazoles | 1991 |
Influence of CGS 15943 A (a nonxanthine adenosine antagonist) on the protection offered by a variety of antiepileptic drugs against maximal electroshock-induced seizures in mice.
Topics: Adenosine; Animals; Anticonvulsants; Disease Susceptibility; Drug Interactions; Electroshock; Epilepsy; Male; Mice; Motor Activity; Quinazolines; Triazoles | 1991 |
Characterization of the binding of a novel nonxanthine adenosine antagonist radioligand, [3H]CGS 15943, to multiple affinity states of the adenosine A1 receptor in the rat cortex.
Topics: 2-Chloroadenosine; Adenosine; Animals; Binding, Competitive; Cerebral Cortex; Dose-Response Relationship, Drug; Phenylisopropyladenosine; Purinergic Antagonists; Pyrazoles; Quinazolines; Rats; Receptors, Purinergic; Triazoles; Tritium | 1991 |
Comparison of the behavioural effects of an adenosine A1/A2-receptor antagonist, CGS 15943A, and an A1-selective antagonist, DPCPX.
Topics: Adenosine; Animals; Behavior, Animal; Dose-Response Relationship, Drug; Exploratory Behavior; Male; Mice; Motor Activity; Purinergic Antagonists; Quinazolines; Triazoles; Xanthines | 1991 |
Effects of CGS-15943A on the relaxations produced by adenosine analogs in human blood vessels.
Topics: Adenosine; Adult; Coronary Vessels; Humans; In Vitro Techniques; Mammary Arteries; Middle Aged; Muscle Relaxation; Muscle, Smooth, Vascular; Potassium Chloride; Quinazolines; Saphenous Vein; Theophylline; Triazoles | 1990 |
Differential antagonism by 1,3-dipropylxanthine-8-cyclopentylxanthine and 9-chloro-2-(2-furanyl)-5,6-dihydro-1,2,4-triazolo(1,5-c)quinazolin-5-im ine of the effects of adenosine derivatives in the presence of isoprenaline on contractile response and cycli
Topics: Adenosine; Adenosine-5'-(N-ethylcarboxamide); Animals; Cyclic AMP; Drug Interactions; Electric Stimulation; Female; Guinea Pigs; Heart; Isoproterenol; Male; Myocardial Contraction; Quinazolines; Receptors, Purinergic; Triazoles; Vasodilator Agents; Xanthines | 1990 |
Cultured vascular smooth muscle cells from porcine coronary artery possess A1 and A2 adenosine receptor activity.
Topics: Adenosine; Adenylyl Cyclase Inhibitors; Analysis of Variance; Animals; Cells, Cultured; Coronary Vessels; Muscle, Smooth, Vascular; Phenylisopropyladenosine; Quinazolines; Receptors, Purinergic; Swine; Triazoles | 1990 |
Rapid, high-sensitivity reversed-phase liquid chromatographic assay for 9-chloro-2-(2-furyl) [1,2,4]triazolo[1,5-c]quinazolin-5-imine and its oxo metabolite in plasma using fluorescence detection.
Topics: Animals; Chemical Phenomena; Chemistry; Chromatography, High Pressure Liquid; Hydrogen-Ion Concentration; Male; Purinergic Antagonists; Quinazolines; Rats; Rats, Inbred Strains; Spectrometry, Fluorescence; Triazoles | 1989 |
Inhibition of renal vasoconstriction induced by intrarenal hypertonic saline by the nonxanthine adenosine antagonist CGS 15943A.
Topics: Adenosine; Animals; Dogs; Quinazolines; Receptors, Purinergic; Renal Circulation; Saline Solution, Hypertonic; Sodium Chloride; Theophylline; Triazoles; Vasoconstriction | 1989 |
Biochemical characterization of the triazoloquinazoline, CGS 15943, a novel, non-xanthine adenosine antagonist.
Topics: Adenosine; Adenosine-5'-(N-ethylcarboxamide); Animals; Binding, Competitive; Brain; Guinea Pigs; Kinetics; Neurotransmitter Agents; Pyrazoles; Quinazolines; Rats; Receptors, Purinergic; Triazoles; Xanthines | 1987 |
Structure-activity profile of a series of novel triazoloquinazoline adenosine antagonists.
Topics: Adenosine; Animals; Chemical Phenomena; Chemistry; Guinea Pigs; In Vitro Techniques; Molecular Conformation; Muscle, Smooth; Quinazolines; Rats; Receptors, Purinergic; Structure-Activity Relationship; Triazoles | 1988 |
Pharmacological characterization of CGS 15943A: a novel nonxanthine adenosine antagonist.
Topics: 2-Chloroadenosine; Adenosine; Animals; Blood Pressure; Coronary Vessels; Dose-Response Relationship, Drug; Guinea Pigs; In Vitro Techniques; Male; Myocardial Contraction; Quinazolines; Rats; Rats, Inbred Strains; Receptors, Purinergic; Trachea; Triazoles | 1987 |
[Antianaphylactic effects of 2-hydrazino-3-arylquinazol-4-ones and 4-aryl-5-oxo-4,5-dihydro-s-triazolo[4,3-a]quinazolines].
Topics: Animals; Hydrazines; Passive Cutaneous Anaphylaxis; Quinazolines; Rats; Triazoles | 1980 |
Effects of the adenosine A1-receptor antagonist on defecation, small intestinal propulsion and gastric emptying in rats.
Topics: Adamantane; Animals; Bisacodyl; Defecation; Gastric Emptying; Gastrointestinal Motility; Imidazoles; Intestine, Small; Male; Purinergic P1 Receptor Antagonists; Pyrazines; Quinazolines; Rats; Rats, Sprague-Dawley; Triazoles; Xanthines | 1995 |
The A1 agonist CCPA reduced bisoxonol-monitored membrane potential depolarization elicited by high K+ in cerebrocortical nerve endings.
Topics: Adenosine; Animals; Cerebral Cortex; Fluorescent Dyes; Male; Membrane Potentials; Nerve Endings; Phenethylamines; Potassium; Purinergic P1 Receptor Agonists; Purinergic P1 Receptor Antagonists; Quinazolines; Rats; Rats, Wistar; Synaptosomes; Thiobarbiturates; Triazoles; Veratridine; Xanthines | 1995 |
Attenuation of hypoxia-induced increases in ventilation by adenosine antagonists in rhesus monkeys.
Topics: Adenosine; Animals; Hypoxia; Macaca mulatta; Male; Phosphodiesterase Inhibitors; Pyrrolidinones; Quinazolines; Respiration; Rolipram; Triazoles | 1995 |
Comparative effects of caffeine and selective phosphodiesterase inhibitors on respiration and behavior in rhesus monkeys.
Topics: 1-Methyl-3-isobutylxanthine; Animals; Behavior, Animal; Caffeine; Carbon Dioxide; Conditioning, Psychological; Female; Macaca mulatta; Male; Phosphodiesterase Inhibitors; Quinazolines; Respiration; Triazoles | 1993 |
Effects of a non-xanthine adenosine antagonist, CGS 15943, and a phosphodiesterase inhibitor, Ro 20-1724, in a light/dark test in mice.
Topics: 4-(3-Butoxy-4-methoxybenzyl)-2-imidazolidinone; Adenosine; Animals; Anxiety; Darkness; Light; Male; Mice; Mice, Inbred ICR; Motor Activity; Phosphodiesterase Inhibitors; Quinazolines; Triazoles | 1994 |
Inhibitory effect of adenosine on electrical activity of frog melanotrophs mediated through A1 purinergic receptors.
Topics: Action Potentials; Adenosine; alpha-MSH; Animals; Cells, Cultured; Electrophysiology; Guanosine 5'-O-(3-Thiotriphosphate); Guanosine Triphosphate; Male; Membrane Potentials; Patch-Clamp Techniques; Pertussis Toxin; Phenylisopropyladenosine; Pituitary Gland; Purinergic P2 Receptor Agonists; Purinergic P2 Receptor Antagonists; Quinazolines; Rana ridibunda; Tachyphylaxis; Theophylline; Triazoles; Virulence Factors, Bordetella | 1994 |
Further investigations into adenosine A1 receptor-mediated contraction in rat colonic muscularis mucosae and its augmentation by certain alkylxanthine antagonists.
Topics: Adenosine; Adenosine-5'-(N-ethylcarboxamide); Animals; Colon; Cyclooxygenase Inhibitors; In Vitro Techniques; Indomethacin; Intestinal Mucosa; Muscle Contraction; Muscle, Smooth; Phosphodiesterase Inhibitors; Purinergic P1 Receptor Agonists; Purinergic P1 Receptor Antagonists; Quinazolines; Rats; Theophylline; Triazoles; Vasodilator Agents; Xanthines | 1995 |
Adenosine A1 and A2 receptor agonists alter cardiac functions and prostacyclin release in the isolated guinea-pig heart.
Topics: 6-Ketoprostaglandin F1 alpha; Adenosine; Animals; Antihypertensive Agents; Cardiac Pacing, Artificial; Cells, Cultured; Coronary Circulation; Dose-Response Relationship, Drug; Endothelium, Vascular; Epoprostenol; Guinea Pigs; Heart; Heart Rate; Male; Myocardium; Phenethylamines; Purinergic P1 Receptor Agonists; Purinergic P1 Receptor Antagonists; Quinazolines; Triazoles; Vasodilation; Ventricular Function, Left; Xanthines | 1994 |
Failure of CGS15943A to block the hypotensive action of agonists acting at the adenosine A3 receptor.
Topics: Adenosine; Adenosine-5'-(N-ethylcarboxamide); Animals; Blood Pressure; Female; Phenethylamines; Purinergic P1 Receptor Agonists; Purinergic P1 Receptor Antagonists; Quinazolines; Rats; Rats, Wistar; Triazoles | 1994 |
CGS 15943, an adenosine A2 receptor antagonist, reduces cerebral ischemic injury in the Mongolian gerbil.
Topics: Animals; Brain Ischemia; Gerbillinae; Male; Motor Activity; Purinergic P1 Receptor Antagonists; Pyramidal Cells; Quinazolines; Triazoles | 1994 |
Pharmacological characterization of A2-adenosine receptors in guinea-pig ventricular cardiomyocytes.
Topics: Adenosine; Adenylate Cyclase Toxin; Adenylyl Cyclases; Animals; Cells, Cultured; Cyclic AMP; Drug Interactions; Female; Guinea Pigs; Heart Ventricles; Isoproterenol; Male; Myocardial Contraction; Myocardium; Papillary Muscles; Pertussis Toxin; Phenethylamines; Quinazolines; Receptors, Adrenergic, beta; Receptors, Purinergic P1; Signal Transduction; Triazoles; Virulence Factors, Bordetella; Xanthines | 1994 |
Effects of the new A2 adenosine receptor antagonist 8FB-PTP, an 8 substituted pyrazolo-triazolo-pyrimidine, on in vitro functional models.
Topics: Adenosine; Adenosine-5'-(N-ethylcarboxamide); Animals; Cattle; In Vitro Techniques; Male; Muscle, Smooth, Vascular; Phosphoric Diester Hydrolases; Platelet Aggregation; Purinergic P1 Receptor Antagonists; Pyrimidines; Quinazolines; Rabbits; Rats; Rats, Sprague-Dawley; Triazoles; Vasodilator Agents; Xanthines | 1994 |
Suppression of lipopolysaccharide-stimulated release of tumor necrosis factor by adenosine: evidence for A2 receptors on rat Kupffer cells.
Topics: Adenosine; Alprostadil; Animals; Bucladesine; Cells, Cultured; Cyclic AMP; Kupffer Cells; Lipopolysaccharides; Nisoldipine; Quinazolines; Rats; Rats, Sprague-Dawley; Receptors, Purinergic P1; Triazoles; Tumor Necrosis Factor-alpha; Xanthines | 1994 |
Effects of CGS 15943, a nonxanthine adenosine antagonist, on behavior in the squirrel monkey.
Topics: Animals; Behavior, Animal; Caffeine; Drug Interactions; Drug Synergism; Male; Purinergic P1 Receptor Antagonists; Pyrrolidinones; Quinazolines; Receptors, Purinergic P1; Rolipram; Saimiri; Time Factors; Triazoles | 1993 |
Myocardial adenosine stimulates release of cyclic adenosine monophosphate from capillary endothelial cells in guinea pig heart.
Topics: Adenosine; Adenosine Deaminase; Adenosine Triphosphate; Alprostadil; Animals; Capillaries; Coronary Vessels; Cyclic AMP; Endothelium, Vascular; Guinea Pigs; Myocardium; Oxygen; Procaterol; Quinazolines; Theophylline; Triazoles; Vasodilation | 1993 |
Discriminative effects of CGS 15943, a competitive adenosine receptor antagonist, in monkeys: comparison to methylxanthines.
Topics: 1-Methyl-3-isobutylxanthine; Animals; Discrimination Learning; Dose-Response Relationship, Drug; Male; Purinergic P1 Receptor Antagonists; Quinazolines; Saimiri; Theophylline; Triazoles; Xanthines | 1996 |
Functional characterization of adenosine A2 receptors in Jurkat cells and PC12 cells using adenosine receptor agonists.
Topics: Adenosine; Adenosine-5'-(N-ethylcarboxamide); Amino Acid Sequence; Animals; Base Sequence; Binding, Competitive; Colforsin; Cyclic AMP; DNA; Humans; Isotope Labeling; Lethal Dose 50; Leukemia, T-Cell; Molecular Sequence Data; PC12 Cells; Phenethylamines; Polymerase Chain Reaction; Purinergic P1 Receptor Agonists; Quinazolines; Rats; Receptors, Purinergic P1; RNA, Messenger; Triazoles; Tumor Cells, Cultured | 1996 |
Binding of the radioligand [3H]-SCH 58261, a new non-xanthine A2A adenosine receptor antagonist, to rat striatal membranes.
Topics: Adenosine; Animals; Binding, Competitive; Corpus Striatum; In Vitro Techniques; Kinetics; Male; Purinergic P1 Receptor Agonists; Purinergic P1 Receptor Antagonists; Pyrimidines; Quinazolines; Radioligand Assay; Rats; Rats, Sprague-Dawley; Receptors, Purinergic P1; Triazoles; Tritium | 1996 |
Blockade of A2a adenosine receptors positively modulates turning behaviour and c-Fos expression induced by D1 agonists in dopamine-denervated rats.
Topics: 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine; Animals; Denervation; Male; Motor Activity; Nerve Tissue Proteins; Oxidopamine; Proto-Oncogene Proteins c-fos; Purinergic P1 Receptor Antagonists; Pyrimidines; Quinazolines; Rats; Rats, Sprague-Dawley; Receptors, Dopamine D1; Rotation; Triazoles; Xanthines | 1996 |
Myocardial adenosine A1 and A2 receptor activities during juvenile and adult stages of development.
Topics: Adenosine; Aging; Animals; Coronary Vessels; Drug Synergism; Heart; Isoproterenol; Male; Myocardial Contraction; Myocardium; Osmolar Concentration; Purinergic P1 Receptor Antagonists; Quinazolines; Rats; Rats, Sprague-Dawley; Receptors, Purinergic P1; Triazoles; Veins; Xanthines | 1996 |
Derivatives of the triazoloquinazoline adenosine antagonist (CGS15943) are selective for the human A3 receptor subtype.
Topics: Adenosine; Affinity Labels; Animals; Binding Sites; Binding, Competitive; Cell Line; Cerebral Cortex; Corpus Striatum; Humans; Magnetic Resonance Spectroscopy; Quinazolines; Rats; Receptors, Purinergic P1; Structure-Activity Relationship; Substrate Specificity; Triazoles | 1996 |
Augmented release of serotonin by adenosine A2a receptor activation and desensitization by CGS 21680 in the rat nucleus tractus solitarius.
Topics: Adenosine; Animals; In Vitro Techniques; Kinetics; Male; Phenethylamines; Purinergic P1 Receptor Agonists; Quinazolines; Rats; Rats, Sprague-Dawley; Receptors, Purinergic P1; Serotonin; Solitary Nucleus; Triazoles; Xanthines | 1996 |
A novel synthesis of 1,2,4-triazolo[1,5-a]isoindolinetrione, 1,2,4-triazolo[1,5-a]pyrimidine and 1,2,4-triazolo[2,3-a]quinazolinedione derivatives and their antibacterial activity.
Topics: Anti-Bacterial Agents; Anti-Infective Agents; Bacteria; Fungi; Gram-Negative Bacteria; Gram-Positive Bacteria; Indoles; Microbial Sensitivity Tests; Pyrimidines; Quinazolines; Triazoles | 1997 |
Adenosine stimulation of DNA synthesis in human endothelial cells.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; 1-Methyl-3-isobutylxanthine; Adenosine; Adenosine Triphosphate; Cells, Cultured; Colforsin; Cyclic AMP; Cyclic AMP-Dependent Protein Kinases; DNA; Endothelium, Vascular; Humans; Kinetics; Poly A; Purinergic P1 Receptor Antagonists; Quinazolines; Tetradecanoylphorbol Acetate; Thioinosine; Thionucleotides; Thymidine; Triazoles; Umbilical Veins | 1997 |
Adenosine A3 receptor agonists protect HL-60 and U-937 cells from apoptosis induced by A3 antagonists.
Topics: Adenosine; Apoptosis; Dihydropyridines; DNA Fragmentation; Dose-Response Relationship, Drug; HL-60 Cells; Humans; Purinergic P1 Receptor Agonists; Purinergic P1 Receptor Antagonists; Pyrazoles; Quinazolines; Triazoles | 1997 |
Adenosine A3 receptors promote degranulation of rat mast cells both in vitro and in vivo.
Topics: Adenosine; Administration, Cutaneous; Animals; Blood Proteins; Cell Degranulation; Cyproheptadine; Dinitrophenols; Female; Humans; In Vitro Techniques; Injections, Intravenous; Male; Mast Cells; Mice; p-Methoxy-N-methylphenethylamine; Pleura; Purinergic P1 Receptor Agonists; Purinergic P1 Receptor Antagonists; Quinazolines; Rats; Rats, Wistar; Receptors, Purinergic P1; Serotonin; Serotonin Antagonists; Serum Albumin; Skin; Theophylline; Triazoles; Xanthines | 1997 |
An endogenous A2B adenosine receptor coupled to cyclic AMP generation in human embryonic kidney (HEK 293) cells.
Topics: 2-Chloroadenosine; Adenosine; Adenosine-5'-(N-ethylcarboxamide); Cells, Cultured; Cyclic AMP; DNA, Complementary; Gene Amplification; Humans; In Vitro Techniques; Kidney; Phenethylamines; Polymerase Chain Reaction; Purinergic P1 Receptor Agonists; Purinergic P1 Receptor Antagonists; Quinazolines; Receptor, Adenosine A2B; Receptors, Purinergic P1; Triazoles | 1997 |
New azole antifungals. 3. Synthesis and antifungal activity of 3-substituted-4(3H)-quinazolinones.
Topics: Animals; Antifungal Agents; Aspergillosis; Aspergillus fumigatus; Candidiasis; Colony Count, Microbial; Fungi; Male; Mice; Molecular Conformation; Quinazolines; Rabbits; Rats; Rats, Sprague-Dawley; Stereoisomerism; Structure-Activity Relationship; Triazoles | 1998 |
Derivatives of the triazoloquinazoline adenosine antagonist (CGS 15943) having high potency at the human A2B and A3 receptor subtypes.
Topics: Animals; Cerebral Cortex; CHO Cells; Cricetinae; Cyclic AMP; Humans; Models, Molecular; Molecular Conformation; Protein Conformation; Purinergic P1 Receptor Antagonists; Quinazolines; Rats; Receptor, Adenosine A2A; Receptor, Adenosine A2B; Receptor, Adenosine A3; Receptors, Purinergic P1; Recombinant Proteins; Structure-Activity Relationship; Triazoles | 1998 |
Binding affinity of adenosine receptor agonists and antagonists at human cloned A3 adenosine receptors.
Topics: Adenosine; Adenosine-5'-(N-ethylcarboxamide); Binding, Competitive; Cell Line; Cloning, Molecular; Humans; Kidney; Purinergic P1 Receptor Agonists; Purinergic P1 Receptor Antagonists; Pyrimidines; Quinazolines; Receptor, Adenosine A3; Receptors, Purinergic P1; Transfection; Triazines; Triazoles | 1998 |
Adenosine A2a receptors increase arterial endothelial cell nitric oxide.
Topics: Adenosine; Adenosine-5'-(N-ethylcarboxamide); Animals; Carotid Arteries; Cells, Cultured; Endothelium, Vascular; Humans; Iliac Artery; Nitric Oxide; Phenethylamines; Purinergic P1 Receptor Agonists; Purinergic P1 Receptor Antagonists; Quinazolines; Receptor, Adenosine A2A; Receptors, Purinergic P1; Swine; Triazines; Triazoles; Xanthines | 1998 |
Comparison of CGS 15943, ZM 241385 and SCH 58261 as antagonists at human adenosine receptors.
Topics: Animals; Cell Line; CHO Cells; Cricetinae; Cyclic AMP; Humans; Purinergic P1 Receptor Antagonists; Pyrimidines; Quinazolines; Rats; Transfection; Triazines; Triazoles; Xanthines | 1999 |
Caffeine, acting on adenosine A(1) receptors, prevents the extinction of cocaine-seeking behavior in mice.
Topics: Animals; Behavior, Animal; Caffeine; Cocaine; Extinction, Psychological; Male; Mice; Mice, Inbred DBA; Purinergic P1 Receptor Antagonists; Pyrimidines; Quinazolines; Reward; Substance Abuse, Intravenous; Theophylline; Triazoles; Xanthines | 1999 |
Discriminative effects of CGS 15943, a competitive adenosine receptor antagonist, have a dopamine component in monkeys.
Topics: Animals; Cocaine; Dextroamphetamine; Discrimination Learning; Dopamine; Dopamine Agonists; Dopamine Antagonists; Generalization, Stimulus; Male; Morphine; Neurons; Norepinephrine; Phencyclidine; Purinergic P1 Receptor Antagonists; Quinazolines; Receptor, Adenosine A2A; Receptors, Biogenic Amine; Saimiri; Selective Serotonin Reuptake Inhibitors; Triazoles | 1999 |
Brief myocardial ischemia attenuates platelet thrombosis in remote, damaged, and stenotic carotid arteries.
Topics: Adenosine; Animals; Blood Platelets; Carotid Artery Thrombosis; Carotid Stenosis; Dogs; Myocardial Ischemia; Quinazolines; Rabbits; Receptors, Purinergic P1; Triazoles; Vascular Patency | 1999 |
In-vitro comparative activity of UR-9825, itraconazole and fluconazole against clinical isolates of Candida spp.
Topics: Antifungal Agents; Candida; Fluconazole; Humans; Itraconazole; Microbial Sensitivity Tests; Quinazolines; Triazoles | 1999 |
Novel triazolo[4,3-a]quinazolinone and bis-triazolo[4,3-a:4,3'-c]quinazolines: synthesis and antitoxoplasmosis effect.
Topics: Animals; Anti-Infective Agents; Coccidiostats; Mice; Pyrimethamine; Quinazolines; Quinazolinones; Toxoplasma; Toxoplasmosis, Animal; Triazoles | 1999 |
Autoradiographic comparison of the potency of several structurally unrelated adenosine receptor antagonists at adenosine A1 and A(2A) receptors.
Topics: Adenosine; Animals; Autoradiography; Binding, Competitive; Brain; Caffeine; In Vitro Techniques; Male; Phenethylamines; Purinergic P1 Receptor Antagonists; Pyrazines; Quinazolines; Rats; Rats, Sprague-Dawley; Receptor, Adenosine A2A; Receptors, Purinergic P1; Theophylline; Triazines; Triazoles; Tritium; Xanthines | 1999 |
Adenosine receptor occupancy suppresses chemoattractant-induced phospholipase D activity by diminishing membrane recruitment of small GTPases.
Topics: Adenosine; Adenosine Deaminase; Adenosine-5'-(N-ethylcarboxamide); ADP-Ribosylation Factor 1; Adult; Caffeine; Cell Membrane; Enzyme Activation; GTP Phosphohydrolases; Humans; In Vitro Techniques; Isoenzymes; Kinetics; N-Formylmethionine Leucyl-Phenylalanine; Neutrophils; Phenethylamines; Phospholipase D; Protein Kinase C; Protein Kinase C-alpha; Purinergic P1 Receptor Antagonists; Quinazolines; Receptor, Adenosine A2A; Receptors, Purinergic P1; rhoA GTP-Binding Protein; Triazoles | 2000 |
The utilization of a unified pharmacophore query in the discovery of new antagonists of the adenosine receptor family.
Topics: Adenosine-5'-(N-ethylcarboxamide); Databases, Factual; Flavonoids; Guanosine 5'-O-(3-Thiotriphosphate); Information Storage and Retrieval; Kinetics; Ligands; Molecular Conformation; Purinergic P1 Receptor Antagonists; Quinazolines; Receptor, Adenosine A3; Receptors, Purinergic P1; Structure-Activity Relationship; Triazoles | 2000 |
ZD4190: an orally active inhibitor of vascular endothelial growth factor signaling with broad-spectrum antitumor efficacy.
Topics: Administration, Oral; Animals; Antineoplastic Agents; Epiphyses; Female; Humans; Hypertrophy; Mice; Neoplasm Transplantation; Quinazolines; Rats; Receptor Protein-Tyrosine Kinases; Receptors, Growth Factor; Receptors, Vascular Endothelial Growth Factor; Transplantation, Heterologous; Triazoles; Tumor Cells, Cultured | 2000 |
Promotion of forskolin-induced long-term potentiation of synaptic transmission by caffeine in area CA1 of the rat hippocampus.
Topics: Adenosine; Animals; Anti-Inflammatory Agents, Non-Steroidal; Caffeine; Central Nervous System Stimulants; Colforsin; Cyclic AMP; Drug Synergism; Excitatory Postsynaptic Potentials; Hippocampus; Long-Term Potentiation; Male; Quinazolines; Rats; Rats, Sprague-Dawley; Synaptic Transmission; Triazoles; Xanthines | 1999 |
Activation of the A3 adenosine receptor affects cell cycle progression and cell growth.
Topics: Adenosine; Adenosine-5'-(N-ethylcarboxamide); Adenylyl Cyclases; Analysis of Variance; Animals; Antineoplastic Agents; Cell Cycle; Cell Line; Cell Membrane; Cell Survival; CHO Cells; Cricetinae; Dihydropyridines; Flow Cytometry; Humans; Purinergic P1 Receptor Antagonists; Quinazolines; Receptor, Adenosine A3; Receptors, Purinergic P1; Transfection; Triazoles | 2000 |
Substituted 1,2,3-triazolo[1,5-a]quinazolines: synthesis and binding to benzodiazepine and adenosine receptors.
Topics: Animals; Binding, Competitive; Cattle; Chemical Phenomena; Chemistry, Physical; In Vitro Techniques; Ligands; Magnetic Resonance Spectroscopy; Neostriatum; Quinazolines; Receptor, Adenosine A2A; Receptors, GABA-A; Receptors, Purinergic P1; Structure-Activity Relationship; Triazoles | 2000 |
Adenosine acts as a chemoprotective agent by stimulating G-CSF production: a role for A1 and A3 adenosine receptors.
Topics: Adenosine; Animals; Bone Marrow Cells; Cell Cycle; Cell Division; Cells, Cultured; Cyclophosphamide; Granulocyte Colony-Stimulating Factor; Humans; Leukocytes, Mononuclear; Male; Mice; Mice, Inbred C57BL; Mice, Inbred ICR; Purinergic P1 Receptor Antagonists; Quinazolines; Receptor, Adenosine A3; Receptors, Purinergic P1; Theobromine; Triazoles; Xanthines | 2000 |
Renal adenosine A3 receptors in the rat: assessment of functional role.
Topics: Animals; Dihydropyridines; Diuresis; Glomerular Filtration Rate; Kidney; Male; Natriuresis; Potassium; Purinergic P1 Receptor Antagonists; Quinazolines; Rats; Rats, Inbred WKY; Receptor, Adenosine A3; Receptors, Purinergic P1; Sodium; Triazoles; Urodynamics; Xanthines | 2000 |
A novel adenosine analog, AMP579, inhibits neutrophil activation, adherence and neutrophil-mediated injury to coronary vascular endothelium.
Topics: Animals; Cell Adhesion; Cell Degranulation; Coronary Vessels; Dogs; Dose-Response Relationship, Drug; Endothelium, Vascular; Female; Imidazoles; In Vitro Techniques; Male; Neutrophil Activation; Neutrophils; Pyridines; Quinazolines; Superoxides; Triazines; Triazoles; Vasodilation; Xanthines | 2000 |
Inhibition of VEGF signal transduction. Identification of ZD4190.
Topics: Antineoplastic Agents; Endothelial Growth Factors; Humans; Lymphokines; Quinazolines; Receptor Protein-Tyrosine Kinases; Receptors, Growth Factor; Receptors, Vascular Endothelial Growth Factor; Signal Transduction; Triazoles; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factors | 2000 |
In vitro antiproliferative effects and mechanism of action of the new triazole derivative UR-9825 against the protozoan parasite Trypanosoma (Schizotrypanum) cruzi.
Topics: Animals; Antiprotozoal Agents; Cell Division; Drug Evaluation, Preclinical; Phospholipids; Quinazolines; Structure-Activity Relationship; Triazoles; Trypanosoma cruzi | 2000 |
Adenosine A(1) and A(3) receptors mediate inhibition of synaptic transmission in rat cortical neurons.
Topics: Adenosine; Animals; Cerebral Cortex; Drug Interactions; Electric Stimulation; Female; In Vitro Techniques; Male; Neurons; Purinergic P1 Receptor Agonists; Purinergic P1 Receptor Antagonists; Quinazolines; Rats; Rats, Wistar; Receptor, Adenosine A3; Receptors, Purinergic P1; Synaptic Transmission; Triazoles; Xanthines | 2001 |
Adenosine modulates cell growth in baby hamster kidney (BHK) cells.
Topics: 4-(3-Butoxy-4-methoxybenzyl)-2-imidazolidinone; Adenosine; Adenosine Kinase; Animals; Cell Division; Cell Line; Cricetinae; Enzyme Inhibitors; Kidney; Mutation; Purinergic P1 Receptor Antagonists; Quinazolines; Receptor, Adenosine A3; Receptors, Purinergic P1; Triazoles | 2000 |
Receptor subtypes mediating adenosine-induced dilation of cerebral arterioles.
Topics: Adenosine; Adenosine Triphosphate; Animals; Antihypertensive Agents; Arterioles; Cerebrovascular Circulation; Dose-Response Relationship, Drug; In Vitro Techniques; Male; Phenethylamines; Quinazolines; Rats; Rats, Sprague-Dawley; Receptors, Purinergic P1; Triazines; Triazoles; Vasodilation | 2001 |
In vitro activities of four novel triazoles against Scedosporium spp.
Topics: Antifungal Agents; Humans; Microbial Sensitivity Tests; Pyrimidines; Quinazolines; Scedosporium; Thiazoles; Triazoles; Voriconazole | 2001 |
A3 receptors mediate rapid inflammatory cell influx into the lungs of sensitized guinea-pigs.
Topics: Adenosine Monophosphate; Animals; Bronchial Provocation Tests; Bronchoconstriction; Dose-Response Relationship, Drug; Guinea Pigs; Histamine; Leukocyte Count; Leukocytes; Lung; Male; Ovalbumin; Pneumonia; Purinergic P1 Receptor Antagonists; Quinazolines; Receptor, Adenosine A3; Receptors, Purinergic P1; Triazoles | 2001 |
Guanosine-induced increase in free cytosolic calcium concentration in mouse astrocytes in primary cultures: does it act on an A3 adenosine receptor?
Topics: Adenosine; Animals; Astrocytes; Brain; Calcium; Cells, Cultured; Cytosol; Dose-Response Relationship, Drug; Extracellular Space; Guanosine; Mice; Phosphodiesterase Inhibitors; Purinergic P1 Receptor Agonists; Purinergic P1 Receptor Antagonists; Quinazolines; Receptor, Adenosine A3; Receptors, Purinergic P1; Theophylline; Triazoles; Xanthines | 2001 |
In vitro antifungal activities of the new triazole UR-9825 against clinically important filamentous fungi.
Topics: Antifungal Agents; Aspergillus fumigatus; Fusarium; Humans; Microbial Sensitivity Tests; Paecilomyces; Quinazolines; Triazoles | 2001 |
Effects of adenosine receptor agonists and antagonists in a genetic animal model of primary paroxysmal dystonia.
Topics: Adenosine; Animals; Caffeine; Cricetinae; Disease Models, Animal; Dose-Response Relationship, Drug; Dystonia; Female; Male; Mesocricetus; Muscle Contraction; Mutation; Phenethylamines; Purinergic P1 Receptor Agonists; Purinergic P1 Receptor Antagonists; Quinazolines; Theobromine; Theophylline; Triazines; Triazoles; Xanthines | 2001 |
Regulation of K(+) current in human airway epithelial cells by exogenous and autocrine adenosine.
Topics: 4,4'-Diisothiocyanostilbene-2,2'-Disulfonic Acid; Adenosine; Affinity Labels; Amiloride; Autocrine Communication; Cell Line; Cell Polarity; Clotrimazole; Diuretics; Epithelial Cells; Equilibrative Nucleoside Transporter 1; Equilibrative-Nucleoside Transporter 2; Growth Inhibitors; Humans; Membrane Transport Proteins; Patch-Clamp Techniques; Potassium; Potassium Channels; Quinazolines; Receptors, Purinergic P1; Respiratory Mucosa; Theobromine; Thioinosine; Triazoles; Uridine; Xanthines | 2001 |
Effects of A(3) adenosine receptor activation and gene knock-out in ischemic-reperfused mouse heart.
Topics: Adenosine; Amino Acids; Animals; Creatine; Heart Rate; Hydrogen-Ion Concentration; Magnetic Resonance Spectroscopy; Mice; Mice, Inbred C57BL; Mice, Knockout; Myocardial Contraction; Myocardial Reperfusion Injury; Myocardium; Perfusion; Phenethylamines; Pipecolic Acids; Purinergic P1 Receptor Antagonists; Quinazolines; Receptor, Adenosine A3; Receptors, Purinergic P1; Triazoles; Xanthines | 2002 |
Targeted deletion of adenosine A(3) receptors augments adenosine-induced coronary flow in isolated mouse heart.
Topics: Adenosine; Animals; Coronary Circulation; Coronary Vessels; Gene Deletion; Heart Rate; Mice; Mice, Knockout; Phenethylamines; Quinazolines; Receptor, Adenosine A3; Receptors, Purinergic P1; Triazoles; Vasodilation; Ventricular Pressure | 2002 |
Vasodilator responses to adenosine and hyperemia are mediated by A(1) and A(2) receptors in the cat vascular bed.
Topics: Adenosine; Adenosine Triphosphate; Animals; Cats; Dose-Response Relationship, Drug; Female; Hemodynamics; Hindlimb; Hyperemia; Male; Perfusion; Purinergic P1 Receptor Agonists; Purinergic P1 Receptor Antagonists; Quinazolines; Receptors, Purinergic P1; Triazoles; Vascular Resistance; Vasodilation; Xanthines | 2002 |
Direct effects of caffeine and theophylline on p110 delta and other phosphoinositide 3-kinases. Differential effects on lipid kinase and protein kinase activities.
Topics: 1-Methyl-3-isobutylxanthine; Animals; Biological Transport; Caffeine; CHO Cells; Cricetinae; Deoxyglucose; Dimerization; Flavins; Glucose; Kinetics; Monosaccharide Transport Proteins; Phosphatidylinositol 3-Kinases; Phosphorylation; Quinazolines; Recombinant Fusion Proteins; Theophylline; Transfection; Triazoles | 2002 |
Effect of novel modulators of protein kinase C activity upon chemotherapy-induced differentiation and apoptosis in myeloid leukemic cells.
Topics: Antineoplastic Agents; Apoptosis; CD11c Antigen; CD4 Antigens; Cell Cycle; Cell Differentiation; Diacylglycerol Kinase; Enzyme Activators; Enzyme Inhibitors; Farnesol; Flow Cytometry; Genes, fos; Genes, jun; Humans; Immunoblotting; Isoenzymes; Leukemia, Myeloid; Naphthalenes; Oncogene Protein p21(ras); Piperidines; Protein Kinase C; Pyrimidinones; Quinazolines; Quinazolinones; Sulfonamides; Thiazoles; Triazoles; Tumor Cells, Cultured | 2002 |
Assessing perfusion and capillary permeability changes induced by a VEGF inhibitor in human tumor xenografts using macromolecular MR imaging contrast media.
Topics: Animals; Capillary Permeability; Contrast Media; Endothelial Growth Factors; Gadolinium; Heterocyclic Compounds; Intercellular Signaling Peptides and Proteins; Lymphokines; Macromolecular Substances; Magnetic Resonance Imaging; Male; Mice; Mice, Nude; Microcirculation; Neoplasm Transplantation; Neovascularization, Pathologic; Organometallic Compounds; Perfusion; Prostatic Neoplasms; Quinazolines; Transplantation, Heterologous; Triazoles; Tumor Cells, Cultured; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factors | 2002 |
Autocrine activation of adenosine A1 receptors blocks D1A but not D1B dopamine receptor desensitization.
Topics: Adenosine; Animals; Autocrine Communication; Cell Line; COS Cells; Cyclic AMP; Dopamine Agonists; Fibroblasts; Mice; Phosphodiesterase Inhibitors; Quinazolines; Receptors, Dopamine D1; Receptors, Dopamine D5; Receptors, Purinergic P1; Time Factors; Transfection; Triazoles; Xanthines | 2002 |
Positive coupling of atypical adenosine A3 receptors on human eosinophils to adenylyl cyclase.
Topics: Adenosine; Adenylyl Cyclases; Adult; Cell Degranulation; Cyclic AMP; Cyclooxygenase Inhibitors; Dose-Response Relationship, Drug; Eosinophils; Histamine; Humans; Phenethylamines; Purinergic P1 Receptor Agonists; Purinergic P1 Receptor Antagonists; Quinazolines; Receptor, Adenosine A2A; Receptor, Adenosine A3; Receptors, Purinergic P1; Triazoles | 2003 |
ATP protects, by way of receptor-mediated mechanisms, against hypoxia-induced injury in renal proximal tubules.
Topics: Adenosine; Adenosine Diphosphate; Adenosine Monophosphate; Adenosine Triphosphate; Animals; Energy Metabolism; Hemolysis; Hypotonic Solutions; Hypoxia; Kidney Tubules, Proximal; Kinetics; L-Lactate Dehydrogenase; Male; Potassium; Quinazolines; Rats; Rats, Sprague-Dawley; Receptors, Purinergic P2; Thionucleotides; Triazoles | 2003 |
The adenosine receptor antagonist CGS15943 reinstates cocaine-seeking behavior and maintains self-administration in baboons.
Topics: Animals; Behavior, Addictive; Cocaine; Dose-Response Relationship, Drug; Male; Papio; Purinergic P1 Receptor Agonists; Purinergic P1 Receptor Antagonists; Quinazolines; Receptors, Purinergic P1; Self Administration; Triazoles | 2003 |
Spinal gabapentin and antinociception: mechanisms of action.
Topics: Acetates; Adrenergic alpha-Antagonists; Adrenergic Antagonists; alpha-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid; Amines; Analgesics; Animals; Atropine; Cyclohexanecarboxylic Acids; Dihydroergocristine; Enzyme Inhibitors; Excitatory Amino Acid Agonists; GABA Antagonists; Gabapentin; gamma-Aminobutyric Acid; Injections, Spinal; Leucine; Male; Mecamylamine; Muscarinic Antagonists; N-Methylaspartate; Naloxone; Narcotic Antagonists; Nicotinic Antagonists; Pain Measurement; Quinazolines; Rats; Rats, Sprague-Dawley; Serine; Spinal Cord; Thapsigargin; Triazoles | 2003 |
A2A and A3 receptors mediate the adenosine-induced relaxation in spontaneously active possum duodenum in vitro.
Topics: Adenosine; Animals; Duodenum; Female; In Vitro Techniques; Male; Opossums; Purinergic P1 Receptor Antagonists; Pyrrolidinones; Quinazolines; Receptors, Purinergic P1; Tetrodotoxin; Time Factors; Triazoles; Xanthines | 2003 |
Binding of HTLV-1 virions to T cells occurs by a temperature and calcium-dependent process and is blocked by certain type 2 adenosine receptor antagonists.
Topics: 2-Chloroadenosine; Adenosine; Adenosine-5'-(N-ethylcarboxamide); Antibodies, Monoclonal; Calcium; Cations, Divalent; Cell Line, Transformed; Human T-lymphotropic virus 1; Humans; Kinetics; Membrane Microdomains; Phenethylamines; Purinergic P1 Receptor Agonists; Quinazolines; T-Lymphocytes; Thermodynamics; Triazoles | 2003 |
Exposure of small mammals, in particular the wood mouse Apodemus sylvaticus, to pesticide seed treatments.
Topics: Animals; Animals, Wild; Digestive System; Environmental Exposure; Environmental Pollutants; Fungicides, Industrial; Liver; Mice; Muridae; Pesticide Residues; Quinazolines; Quinazolinones; Seeds; Time Factors; Triazoles; Triticum | 2003 |
Efficacy of albaconazole (UR-9825) in treatment of disseminated Scedosporium prolificans infection in rabbits.
Topics: Animals; Antifungal Agents; Male; Mycetoma; Quinazolines; Rabbits; Scedosporium; Survival Analysis; Triazoles | 2003 |
In vitro susceptibilities of Malassezia species to a new triazole, albaconazole (UR-9825), and other antifungal compounds.
Topics: Antifungal Agents; Drug Resistance, Fungal; Fluconazole; Flucytosine; In Vitro Techniques; Itraconazole; Ketoconazole; Malassezia; Microbial Sensitivity Tests; Pyrimidines; Quinazolines; Triazoles; Voriconazole | 2003 |
Dynamic contrast-enhanced MRI of vascular changes induced by the VEGF-signalling inhibitor ZD4190 in human tumour xenografts.
Topics: Animals; Contrast Media; Female; Gadolinium DTPA; Humans; Magnetic Resonance Imaging; Male; Mice; Mice, Nude; Neoplasm Transplantation; Neoplasms, Experimental; Quinazolines; Transplantation, Heterologous; Triazoles; Vascular Endothelial Growth Factor A | 2003 |
Antagonist pharmacology of adenosine A2B receptors from rat, guinea pig and dog.
Topics: Adenosine A2 Receptor Antagonists; Adenosine-5'-(N-ethylcarboxamide); Animals; Dogs; Dose-Response Relationship, Drug; Female; Guinea Pigs; In Vitro Techniques; Male; Muscle Relaxation; Quinazolines; Rats; Receptor, Adenosine A2B; Species Specificity; Triazoles | 2003 |
Effects of adenosine receptor antagonists on pial arteriolar dilation during carbon dioxide inhalation.
Topics: Adenosine; Administration, Inhalation; Animals; Caffeine; Carbon Dioxide; Cerebral Cortex; Cerebral Veins; Cerebrovascular Circulation; Drug Interactions; Male; NG-Nitroarginine Methyl Ester; Nitric Oxide Synthase; Purinergic P1 Receptor Antagonists; Quinazolines; Rats; Rats, Sprague-Dawley; Triazines; Triazoles; Vasodilation; Vasodilator Agents; Xanthines | 2003 |
Modeling the adenosine receptors: comparison of the binding domains of A2A agonists and antagonists.
Topics: Adenosine A2 Receptor Agonists; Adenosine A2 Receptor Antagonists; Adenosine-5'-(N-ethylcarboxamide); Animals; Binding Sites; COS Cells; Humans; Hydrogen Bonding; Hydrophobic and Hydrophilic Interactions; Ligands; Models, Molecular; Mutagenesis, Site-Directed; Protein Conformation; Quinazolines; Radioligand Assay; Receptors, Adenosine A2; Triazoles | 2003 |
Reduced capillary perfusion and permeability in human tumour xenografts treated with the VEGF signalling inhibitor ZD4190: an in vivo assessment using dynamic MR imaging and macromolecular contrast media.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Capillary Permeability; Cell Line, Tumor; Contrast Media; Magnetic Resonance Angiography; Male; Mice; Mice, Nude; Neoplasm Transplantation; Neoplasms, Experimental; Neovascularization, Pathologic; Quinazolines; Triazoles; Vascular Endothelial Growth Factor A | 2003 |
Synthesis of 4-amino-6-(hetero)arylalkylamino-1,2,4-triazolo[4,3-a]quinoxalin-1-one derivatives as potent A(2A) adenosine receptor antagonists.
Topics: Adenosine A1 Receptor Antagonists; Adenosine A2 Receptor Antagonists; Adenosine A3 Receptor Antagonists; Animals; Binding Sites; Cattle; CHO Cells; Cricetinae; Humans; Molecular Structure; Quinazolines; Structure-Activity Relationship; Triazoles | 2003 |
Synthesis and in vitro antibacterial evaluation of novel imidazo[2',1':5,1]-1,2,4-triazolo[4,3-c]-quinazoline derivatives of 5-thioxo-1, 2, 4-triazole, 4-oxothiazolidine, and their open-chain counterparts.
Topics: Anti-Bacterial Agents; Colony Count, Microbial; Gram-Negative Bacteria; Gram-Positive Bacteria; Microbial Sensitivity Tests; Quinazolines; Quinazolinones; Structure-Activity Relationship; Thiazoles; Triazoles | 2003 |
In vitro and in vivo efficacies of the new triazole albaconazole against Cryptococcus neoformans.
Topics: Animals; Antifungal Agents; Colony Count, Microbial; Cryptococcus neoformans; Fluconazole; Meningitis, Cryptococcal; Microbial Sensitivity Tests; Quinazolines; Rabbits; Survival Analysis; Triazoles | 2004 |
In vitro interactions of licensed and novel antifungal drugs against Fusarium spp.
Topics: Amphotericin B; Antifungal Agents; Drug Interactions; Drug Resistance, Fungal; Fusarium; Humans; Itraconazole; Microbial Sensitivity Tests; Naphthalenes; Pyrimidines; Quinazolines; Sensitivity and Specificity; Terbinafine; Thiazoles; Triazoles; Voriconazole | 2004 |
Inosine stimulates chemotaxis, Ca2+-transients and actin polymerization in immature human dendritic cells via a pertussis toxin-sensitive mechanism independent of adenosine receptors.
Topics: Actins; Antigens, CD; Caffeine; Calcium; Cell Differentiation; Chemotaxis; Cytokines; Dendritic Cells; Dose-Response Relationship, Drug; Flow Cytometry; Histocompatibility Antigens Class I; Humans; Inosine; Pertussis Toxin; Purinergic P1 Receptor Antagonists; Quinazolines; Receptors, Purinergic P1; Triazoles; Xanthines | 2004 |
Measurement of the sign and the magnitude of heteronuclear coupling constants from spin-state-edited J-cross-polarization NMR experiments.
Topics: Carbon; Data Interpretation, Statistical; Magnetic Resonance Spectroscopy; Menthol; Molecular Conformation; Nuclear Magnetic Resonance, Biomolecular; Protons; Quinazolines; Sensitivity and Specificity; Spin Labels; Triazoles | 2004 |
VEGF receptor antagonism blocks arteriogenesis, but only partially inhibits angiogenesis, in skeletal muscle of exercise-trained rats.
Topics: Animals; Capillaries; Collateral Circulation; Gene Expression; Kidney; Ligation; Male; Muscle, Skeletal; Neovascularization, Physiologic; Physical Conditioning, Animal; Physical Exertion; Quinazolines; Rats; Rats, Sprague-Dawley; Receptors, Vascular Endothelial Growth Factor; Triazoles | 2005 |
In vitro antifungal susceptibility of Cryptococcus gattii.
Topics: Antifungal Agents; Cryptococcus; Cryptococcus neoformans; Humans; Microbial Sensitivity Tests; Quinazolines; Thiazoles; Triazoles | 2004 |
Activity of the new triazole derivative albaconazole against Trypanosoma (Schizotrypanum) cruzi in dog hosts.
Topics: Animals; Chagas Disease; Dogs; Enzyme-Linked Immunosorbent Assay; Immunoglobulin G; Monocytes; Nifurtimox; Nitroimidazoles; Quinazolines; Reverse Transcriptase Polymerase Chain Reaction; Triazoles; Trypanocidal Agents; Trypanosoma cruzi | 2004 |
Varicosity-Schwann cell interactions mediated by ATP in the mouse vas deferens.
Topics: Adenosine Triphosphate; Adrenergic Fibers; Aniline Compounds; Animals; Caffeine; Calcium; Cell Count; Drug Interactions; Electric Stimulation; Estrenes; Evoked Potentials; Fluorescent Dyes; Immunohistochemistry; In Vitro Techniques; Male; Mice; Mice, Inbred BALB C; Organic Chemicals; Phosphodiesterase Inhibitors; Platelet Aggregation Inhibitors; Pyridoxal Phosphate; Pyrrolidinones; Quinazolines; S100 Proteins; Schwann Cells; Suramin; Time Factors; Triazoles; Uridine Triphosphate; Vas Deferens; Xanthenes | 2005 |
Antiinflammatory effect of A3 adenosine receptor agonists in murine autoimmune arthritis models.
Topics: Adenosine; Adenosine A3 Receptor Agonists; Adenosine A3 Receptor Antagonists; Animals; Anti-Inflammatory Agents; Arthritis, Experimental; Collagen; Dose-Response Relationship, Drug; Female; Joints; Lymph Nodes; Male; Mice; Mice, Inbred DBA; Quinazolines; Rats; Receptor, Adenosine A3; Spleen; Triazoles; Tumor Necrosis Factor-alpha | 2005 |
Synthesis and pharmacological investigation of novel 1-substituted-4-phenyl-1,2,4-triazolo[4,3-a]quinazolin-5(4H)-ones as a new class of H1-antihistaminic agents.
Topics: Animals; Bronchial Spasm; Chlorpheniramine; Cyclization; Guinea Pigs; Histamine H1 Antagonists; Hypnotics and Sedatives; Quinazolines; Structure-Activity Relationship; Triazoles | 2005 |
Adenosine signaling promotes neuronal, catecholaminergic differentiation of primary neural crest cells and CNS-derived CAD cells.
Topics: 1-Methyl-3-isobutylxanthine; Adenosine; Adenosine A2 Receptor Agonists; Adenosine A2 Receptor Antagonists; Adenosine Deaminase; Adenosine Deaminase Inhibitors; Adenosine-5'-(N-ethylcarboxamide); Adrenal Medulla; Animals; Bone Morphogenetic Protein 2; Bone Morphogenetic Proteins; Catecholamines; Cell Differentiation; Cell Line; Cells, Cultured; Chromaffin Cells; Coturnix; Culture Media, Serum-Free; Cyclic AMP; Neural Crest; Neurons; Quinazolines; Receptor, Adenosine A2A; Receptor, Adenosine A2B; Signal Transduction; Sympathetic Nervous System; Transforming Growth Factor beta; Triazoles; Tyrosine 3-Monooxygenase | 2005 |
Does conversion of ATP to adenosine terminate ATP-stimulated vasopressin release from hypothalamo-neurohypophyseal explants?
Topics: 5'-Nucleotidase; Adenosine; Adenosine A1 Receptor Antagonists; Adenosine Triphosphate; Animals; Enzyme Inhibitors; Hypothalamo-Hypophyseal System; Male; Organ Culture Techniques; Pituitary Gland, Posterior; Purinergic P1 Receptor Antagonists; Quinazolines; Rats; Rats, Sprague-Dawley; Receptor, Adenosine A1; Receptors, Purinergic P1; Supraoptic Nucleus; Time Factors; Triazoles; Vasopressins; Water-Electrolyte Balance; Xanthines | 2005 |
Modulation of seizures and synaptic plasticity by adenosinergic receptors in an experimental model of temporal lobe epilepsy induced by pilocarpine in rats.
Topics: 5'-Nucleotidase; Adenosine; Animals; Dentate Gyrus; Disease Models, Animal; Epilepsy, Temporal Lobe; Hippocampus; In Situ Nick-End Labeling; Male; Neuronal Plasticity; Neuroprotective Agents; Pilocarpine; Purinergic P1 Receptor Antagonists; Quinazolines; Rats; Rats, Wistar; Receptors, Purinergic P1; Status Epilepticus; Synapses; Triazoles; Xanthines | 2005 |
Antimicrobial activity of some substituted triazoloquinazolines.
Topics: Anti-Bacterial Agents; Antifungal Agents; Bacillus subtilis; Fungi; Microbial Sensitivity Tests; Quinazolines; Staphylococcus aureus; Structure-Activity Relationship; Triazoles | 2005 |
Antinociceptive, brain-penetrating derivatives related to improgan, a non-opioid analgesic.
Topics: Algorithms; Analgesics; Animals; Behavior, Animal; Benzothiazoles; Brain; Cimetidine; Dose-Response Relationship, Drug; Histamine H2 Antagonists; Injections, Intraventricular; Male; Mice; Molecular Structure; Pain; Pain Measurement; Phenoxypropanolamines; Piperidines; Quinazolines; Quinazolinones; Rats; Rats, Sprague-Dawley; Thiazoles; Time Factors; Triazoles | 2005 |
Cryptococcus gattii: in vitro susceptibility to the new antifungal albaconazole versus fluconazole and voriconazole.
Topics: Animals; Antifungal Agents; Cryptococcosis; Cryptococcus; Fluconazole; Humans; Microbial Sensitivity Tests; Pyrimidines; Quinazolines; Soil Microbiology; Triazoles; Voriconazole | 2005 |
Development and exploitation of CK2 inhibitors.
Topics: Adenosine Triphosphate; Antineoplastic Agents; Apoptosis; Benzimidazoles; Binding Sites; Casein Kinase II; Cell Line; Cell Membrane Permeability; Coumarins; Holoenzymes; Humans; Ligands; Mutation; Protein Kinase Inhibitors; Quinazolines; Structure-Activity Relationship; Triazoles | 2005 |
Inosine released after hypoxia activates hepatic glucose liberation through A3 adenosine receptors.
Topics: Adenosine; Adenosine A3 Receptor Antagonists; Animals; Calcium; Cell Hypoxia; Cyclic AMP; Gluconeogenesis; Glucose; Glycogen Phosphorylase; Glycogenolysis; Hepatocytes; Inosine; Liver; Male; Phylogeny; Purinergic P1 Receptor Agonists; Purinergic P1 Receptor Antagonists; Quinazolines; Rats; Rats, Wistar; Receptor, Adenosine A3; Receptors, G-Protein-Coupled; Receptors, Purinergic; Receptors, Purinergic P1; Triazoles; Urea | 2006 |
Purine P1 receptor-dependent immunostimulatory effects of antiviral acyclic analogues of adenine and 2,6-diaminopurine.
Topics: 2-Aminopurine; Adenine; Adjuvants, Immunologic; Animals; Anti-HIV Agents; Caffeine; Cell Survival; Cells, Cultured; Chemokine CCL3; Chemokine CCL4; Chemokine CCL5; Dihydropyridines; Dose-Response Relationship, Drug; Female; Flavins; Humans; Interleukin-10; Lipopolysaccharides; Macrophage Inflammatory Proteins; Macrophages; Mice; Mice, Inbred C57BL; Molecular Structure; Organophosphonates; Purinergic P1 Receptor Antagonists; Quinazolines; Receptors, Purinergic P1; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Theophylline; Triazoles; Tumor Necrosis Factor-alpha | 2006 |
A3 adenosine receptor antagonists delay irreversible synaptic failure caused by oxygen and glucose deprivation in the rat CA1 hippocampus in vitro.
Topics: Action Potentials; Adenosine A3 Receptor Antagonists; Animals; Brain Ischemia; Hippocampus; Hypoglycemia; Hypoxia; Male; Pyridines; Quinazolines; Rats; Rats, Wistar; Receptor, Adenosine A3; Synaptic Transmission; Time Factors; Triazoles | 2006 |
Schwann cells in rat vascular autonomic nerves activated via purinergic receptors.
Topics: Adenosine; Adenosine Triphosphate; Animals; Autonomic Nervous System; Calcium; Quinazolines; Rats; Rats, Wistar; Receptors, Purinergic; Schwann Cells; Splanchnic Circulation; Suramin; Triazoles; Uridine Triphosphate | 2006 |
Radioligand binding and functional responses of ligands for human recombinant adenosine A(3) receptors.
Topics: Adenosine; Animals; Binding, Competitive; CHO Cells; Cricetinae; Cyclic AMP; Guanosine 5'-O-(3-Thiotriphosphate); Iodine Radioisotopes; Ligands; Magnesium Chloride; Quinazolines; Radioligand Assay; Receptor, Adenosine A3; Recombinant Proteins; Transfection; Triazoles | 2006 |
Cytotoxicity and detection of damage to DNA by 3-(5-nitro-2-thienyl)-9-chloro-5-morpholin-4-yl[1,2,4]triazolo[4,3-c] quinazoline on human cancer cell line HeLa.
Topics: Animals; Antineoplastic Agents; Cattle; DNA Damage; Drug Screening Assays, Antitumor; HeLa Cells; Humans; Quinazolines; Triazoles | 2005 |
Synthesis and evaluation as NOP ligands of some spiro[piperidine-4,2'(1'H)-quinazolin]-4'(3'H)-ones and spiro[piperidine-4,5'(6'H)-[1,2,4]triazolo[1,5-c]quinazolines].
Topics: Benzyl Compounds; Cell Line; Cell Membrane; Cyclohexanes; Drug Design; Guanosine 5'-O-(3-Thiotriphosphate); Humans; Ligands; Methylation; Models, Molecular; Molecular Conformation; Nociceptin Receptor; Quinazolines; Receptors, Opioid; Receptors, Opioid, delta; Receptors, Opioid, kappa; Receptors, Opioid, mu; Spiro Compounds; Structure-Activity Relationship; Triazoles | 2006 |
In vitro activities of new and conventional antimycotics against fluconazole-susceptible and non-susceptible Brazilian Candida spp. isolates.
Topics: Antifungal Agents; Brazil; Candida; Candidiasis; Drug Resistance, Fungal; Fluconazole; Humans; Microbial Sensitivity Tests; Quinazolines; Thiazoles; Triazoles | 2006 |
Nucleotide analogues with immunobiological properties: 9-[2-Hydroxy-3-(phosphonomethoxy)propyl]-adenine (HPMPA), -2,6-diaminopurine (HPMPDAP), and their N6-substituted derivatives.
Topics: Adenine; Animals; Caffeine; Cell Survival; Cytokines; Dihydropyridines; Dose-Response Relationship, Drug; Female; Gene Expression; Interferon-gamma; Lipopolysaccharides; Macrophages, Peritoneal; Mice; Mice, Inbred C57BL; Molecular Structure; Nitric Oxide; Nitric Oxide Synthase Type II; Nucleotides; Organophosphonates; Organophosphorus Compounds; Purinergic P1 Receptor Antagonists; Quinazolines; Receptors, Purinergic P1; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Triazoles | 2006 |
Cytotoxic/antiproliferative effects of new [1,2,4]triazolo[4,3-c] quinazolines in tumor cell lines HeLa and B16.
Topics: Animals; Antineoplastic Agents; Cell Death; Cell Proliferation; DNA Damage; Drug Screening Assays, Antitumor; HeLa Cells; Humans; Inhibitory Concentration 50; Melanoma, Experimental; Mice; Quinazolines; Triazoles | 2006 |
Inhibitory responses to exogenous adenosine in murine proximal and distal colon.
Topics: Adenosine; Animals; Colon; Dose-Response Relationship, Drug; Enzyme Inhibitors; Male; Mice; Mice, Inbred C57BL; Muscle Contraction; Muscle, Smooth; NG-Nitroarginine Methyl Ester; Nitric Oxide; Nitric Oxide Synthase Type III; Purinergic P1 Receptor Antagonists; Quinazolines; Receptors, Purinergic P1; Signal Transduction; Theobromine; Triazoles; Xanthines | 2006 |
Inhibition of vascular endothelial growth factor (VEGF)-165 and semaphorin 3A-mediated cellular invasion and tumor growth by the VEGF signaling inhibitor ZD4190 in human colon cancer cells and xenografts.
Topics: Animals; Cisplatin; Colonic Neoplasms; Enzyme Inhibitors; Female; Humans; Lung Neoplasms; Mice; Mice, Nude; Mitogen-Activated Protein Kinases; Neoplasm Invasiveness; Piperidines; Quinazolines; Receptors, Vascular Endothelial Growth Factor; Semaphorin-3A; Signal Transduction; Triazoles; Vascular Endothelial Growth Factor A; Xenograft Model Antitumor Assays | 2006 |
Synthesis and pharmacological investigation of novel 1-substituted-4-(4-substituted phenyl)-4H-[1,2,4]triazolo[4,3-a]quinazolin-5-ones as a new class of H1-antihistamine agents.
Topics: Animals; Bronchi; Bronchial Spasm; Guinea Pigs; Histamine H1 Antagonists, Non-Sedating; Male; Motor Activity; Quinazolines; Receptors, Histamine H1; Sleep; Structure-Activity Relationship; Triazoles | 2006 |
Evaluation of antiangiogenic treatment effects on tumors' microcirculation by Bayesian physiological pharmacokinetic modeling and magnetic resonance imaging.
Topics: Animals; Bayes Theorem; Contrast Media; Heterocyclic Compounds; Magnetic Resonance Imaging; Male; Mice; Mice, Nude; Microcirculation; Neoplasm Transplantation; Neoplasms; Neovascularization, Pathologic; Organometallic Compounds; Quinazolines; Triazoles; Xenograft Model Antitumor Assays | 2006 |
Antifungal susceptibilities of the species of the Pseudallescheria boydii complex.
Topics: Amphotericin B; Antifungal Agents; Candida; Drug Resistance, Fungal; Echinocandins; Fluconazole; Flucytosine; Humans; Itraconazole; Ketoconazole; Lipopeptides; Lipoproteins; Micafungin; Microbial Sensitivity Tests; Naphthalenes; Peptides, Cyclic; Pseudallescheria; Pyrimidines; Quality Control; Quinazolines; Scedosporium; Terbinafine; Thiazoles; Triazoles; Voriconazole | 2006 |
Stimulation of adenosine A1 and A2A receptors by AMP in the submucosal plexus of guinea pig small intestine.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Action Potentials; Adenosine; Adenosine A1 Receptor Antagonists; Adenosine A2 Receptor Antagonists; Adenosine Diphosphate; Adenosine Monophosphate; Animals; Boron Compounds; Enzyme Inhibitors; Estrenes; Excitatory Postsynaptic Potentials; Guinea Pigs; Ileum; Indoles; Male; Maleimides; Norepinephrine; Phenethylamines; Pyrrolidinones; Quinazolines; Receptor, Adenosine A1; Receptor, Adenosine A2A; Signal Transduction; Submucous Plexus; Synaptic Transmission; Tetrodotoxin; Theophylline; Triazines; Triazoles | 2007 |
Liver toxicity after treatment with gefitinib and anastrozole: drug-drug interactions through cytochrome p450?
Topics: Anastrozole; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemical and Drug Induced Liver Injury; Cytochrome P-450 Enzyme System; Drug Interactions; Female; Gefitinib; Humans; Isoenzymes; Lymphatic Metastasis; Middle Aged; Nitriles; Quinazolines; Triazoles | 2006 |
Synthesis of tetrahydrobenzimidazo[1,2-b]quinazolin-1(2H)-one and tetrahydro-1,2,4-triazolo[5,1-b]quinazolin-8(4H)-one ring systems under solvent-free conditions.
Topics: Aldehydes; Amitrole; Benzimidazoles; Combinatorial Chemistry Techniques; Molecular Structure; Quinazolines; Solvents; Triazoles | 2006 |
New [1,2,4]triazolo[4,3-c]quinazoline enhances cisplatin- and temozolomide-induced growth inhibition and apoptosis in HL-60 cells.
Topics: Antineoplastic Agents; Apoptosis; Cell Cycle; Cell Proliferation; Cisplatin; Dacarbazine; DNA Fragmentation; Dose-Response Relationship, Drug; Drug Synergism; HL-60 Cells; Humans; Molecular Structure; Quinazolines; Temozolomide; Triazoles | 2007 |
Identification of nonpeptide CCR5 receptor agonists by structure-based virtual screening.
Topics: Amino Acid Sequence; CCR5 Receptor Antagonists; Models, Molecular; Molecular Sequence Data; Molecular Structure; Piperazines; Piperidines; Protein Structure, Tertiary; Pyridazines; Pyrrolidines; Quantitative Structure-Activity Relationship; Quinazolines; Receptors, CCR5; Sequence Homology, Amino Acid; Triazoles | 2007 |
Indomethacin stimulates activity and expression of ecto-5'-nucleotidase/CD73 in glioma cell lines.
Topics: 5'-Nucleotidase; Actins; Adenosine Diphosphate; Adenosine Monophosphate; Adenosine Triphosphate; Anti-Inflammatory Agents, Non-Steroidal; Cell Line, Tumor; Cell Proliferation; Dimethyl Sulfoxide; Dose-Response Relationship, Drug; Enzyme Activation; Flow Cytometry; Gene Expression Regulation, Enzymologic; Glioma; Humans; Indomethacin; Purinergic P1 Receptor Agonists; Purinergic P1 Receptor Antagonists; Quinazolines; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Theophylline; Time Factors; Triazoles; Xanthines | 2007 |
Neutral 5-substituted 4-anilinoquinazolines as potent, orally active inhibitors of erbB2 receptor tyrosine kinase.
Topics: Administration, Oral; Aniline Compounds; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cell Proliferation; Dogs; Drug Synergism; Mice; Molecular Structure; Neoplasms; Quinazolines; Rats; Receptor, ErbB-2; Triazoles; Xenograft Model Antitumor Assays | 2007 |
Synthesis and pharmacological investigation of novel 4-(2-methylphenyl)-1-substituted-4H-[1,2,4]triazolo[4,3-a]quinazolin-5-ones as new class of H(1)-antihistaminic agents.
Topics: Animals; Central Nervous System; Guinea Pigs; Histamine H1 Antagonists; Male; Methylation; Molecular Structure; Quinazolines; Structure-Activity Relationship; Triazoles | 2008 |
Dual purinergic synaptic transmission in the human enteric nervous system.
Topics: Aniline Compounds; Calcium; Chloride Channels; Electric Stimulation; Enteric Nervous System; Fluorescent Dyes; Humans; Microscopy, Confocal; Nerve Fibers; Neurons; Obesity; Quinazolines; Receptors, Purinergic; Receptors, Purinergic P2; Receptors, Purinergic P2Y1; Submucous Plexus; Synaptic Transmission; Triazoles; Type C Phospholipases; Vasoactive Intestinal Peptide; Xanthenes | 2008 |
[Identification and susceptibility against fluconazole and albaconazole of 100 yeasts' strains isolated from vaginal discharge].
Topics: Adult; Antifungal Agents; Body Fluids; Candida; Candida albicans; Candida glabrata; Candidiasis, Vulvovaginal; Drug Resistance, Fungal; Female; Fluconazole; Humans; Microbial Sensitivity Tests; Middle Aged; Quinazolines; Triazoles; Trichosporon; Vagina | 2007 |
Effects of gefitinib (Iressa) on mammary cancers: preventive studies with varied dosages, combinations with vorozole or targretin, and biomarker changes.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Bexarotene; Biomarkers, Tumor; Carcinogens; Cell Proliferation; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; Drug Therapy, Combination; ErbB Receptors; Female; Gefitinib; Immunoenzyme Techniques; Mammary Neoplasms, Experimental; Methylnitrosourea; Phosphorylation; Quinazolines; Rats; Rats, Sprague-Dawley; Tetrahydronaphthalenes; Triazoles | 2008 |
[A new therapeutic principle for migraine].
Topics: Azepines; Calcitonin Gene-Related Peptide; Humans; Imidazoles; Migraine Disorders; Piperazines; Quinazolines; Serotonin Receptor Agonists; Treatment Outcome; Triazoles; Tryptamines; Vasodilator Agents | 2008 |
Inosine and equilibrative nucleoside transporter 2 contribute to hypoxic preconditioning in the murine cardiomyocyte HL-1 cell line.
Topics: Adenosine; Adenosine A1 Receptor Antagonists; Adenosine A3 Receptor Antagonists; Animals; Cell Hypoxia; Cell Line; Cell Survival; Equilibrative Nucleoside Transporter 1; Equilibrative-Nucleoside Transporter 2; Inosine; Mice; Myocytes, Cardiac; Nucleoside Transport Proteins; Quinazolines; Receptor, Adenosine A1; Receptor, Adenosine A3; Thioinosine; Triazoles; Up-Regulation; Xanthines | 2008 |
Estrogen receptor (ER) and epidermal growth factor receptor (EGFR) as targets for dual lung cancer therapy: not just a case?
Topics: Adenocarcinoma; Antineoplastic Agents; Diagnosis, Differential; Drug Therapy, Combination; ErbB Receptors; Female; Follow-Up Studies; Gefitinib; Humans; Letrozole; Lung Neoplasms; Middle Aged; Nitriles; Protein Kinase Inhibitors; Quinazolines; Receptors, Estrogen; Skin Neoplasms; Triazoles | 2008 |
Adenosine receptor subtypes in the airways responses to 5'-adenosine monophosphate inhalation of sensitized guinea-pigs.
Topics: Adenosine Monophosphate; Administration, Inhalation; Animals; Anti-Inflammatory Agents; Asthma; Bronchial Hyperreactivity; Bronchoalveolar Lavage Fluid; Bronchoconstriction; Bronchodilator Agents; Dexamethasone; Dose-Response Relationship, Drug; Guinea Pigs; Immunization; Purinergic P1 Receptor Antagonists; Purines; Quinazolines; Receptors, Purinergic P1; Triazines; Triazoles; Xanthines | 2008 |
Transient inhibition of ATM kinase is sufficient to enhance cellular sensitivity to ionizing radiation.
Topics: Animals; Ataxia Telangiectasia Mutated Proteins; Cell Cycle; Cell Cycle Proteins; DNA Damage; DNA-Binding Proteins; DNA, Neoplasm; HeLa Cells; Humans; Infrared Rays; Mice; Phosphoinositide-3 Kinase Inhibitors; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins c-abl; Quinazolines; Radiation Tolerance; Signal Transduction; Triazoles; Tumor Suppressor Proteins | 2008 |
Adenosine receptor antagonists alter the stability of human epileptic GABAA receptors.
Topics: Adenosine; Adenosine Deaminase; Adult; Animals; Anticonvulsants; Cerebral Cortex; Epilepsy; Female; GABA-A Receptor Agonists; gamma-Aminobutyric Acid; Humans; Male; Neurons; Oocytes; Purinergic P1 Receptor Antagonists; Pyramidal Tracts; Pyrimidines; Quinazolines; Rats; Receptors, GABA-A; Triazoles; Xanthines; Xenopus | 2008 |
Caffeine modulates TNF-alpha production by cord blood monocytes: the role of adenosine receptors.
Topics: Acetamides; Adenosine A1 Receptor Antagonists; Adenosine A2 Receptor Antagonists; Adenosine A3 Receptor Antagonists; Adult; Blotting, Western; Caffeine; Cells, Cultured; Cyclic AMP; Dose-Response Relationship, Drug; Enzyme-Linked Immunosorbent Assay; Fetal Blood; Humans; Infant, Newborn; Interleukins; Lipopolysaccharides; Middle Aged; Monocytes; Purines; Quinazolines; Receptor, Adenosine A1; Receptor, Adenosine A2A; Receptor, Adenosine A2B; Receptor, Adenosine A3; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Time Factors; Triazines; Triazoles; Tumor Necrosis Factor-alpha; Xanthines | 2009 |
Use of a novel Arg-Gly-Asp radioligand, 18F-AH111585, to determine changes in tumor vascularity after antitumor therapy.
Topics: Animals; Antineoplastic Agents; Carcinoma, Lewis Lung; Carcinoma, Non-Small-Cell Lung; Dose-Response Relationship, Drug; Mice; Neoplasms; Oligopeptides; Paclitaxel; Peptides; Polyethylene Glycols; Positron-Emission Tomography; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Quinazolines; Receptors, Vascular Endothelial Growth Factor; Tissue Distribution; Triazoles | 2009 |
San Antonio Breast Cancer Symposium.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Breast Neoplasms; Diphosphonates; Everolimus; Female; Humans; Imidazoles; Lapatinib; Letrozole; Nitriles; Quinazolines; Sirolimus; Tamoxifen; Trastuzumab; Triazoles; Zoledronic Acid | 2009 |
Multiple receptor subtypes and multiple mechanisms of dilation are involved in vascular network dilation caused by adenosine.
Topics: Adenosine; Animals; Arterioles; Cricetinae; Drug Antagonism; Endothelium, Vascular; Flavins; Mesocricetus; Methacholine Chloride; Nitroprusside; Purinergic P1 Receptor Antagonists; Quinazolines; Receptors, Purinergic P1; Triazines; Triazoles; Vasodilation; Vasodilator Agents | 2009 |
Combined Src and aromatase inhibition impairs human breast cancer growth in vivo and bypass pathways are activated in AZD0530-resistant tumors.
Topics: Anastrozole; Animals; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Benzodioxoles; Breast Neoplasms; Cell Cycle; Cell Line, Tumor; Cell Proliferation; CSK Tyrosine-Protein Kinase; Cyclin-Dependent Kinase Inhibitor p27; Drug Resistance, Neoplasm; Female; Humans; Immunohistochemistry; Ki-67 Antigen; Mammary Neoplasms, Experimental; Mice; Mice, Inbred BALB C; Mice, Nude; Mitogen-Activated Protein Kinases; Nitriles; Phosphatidylinositol 3-Kinases; Protein-Tyrosine Kinases; Quinazolines; Signal Transduction; src-Family Kinases; Triazoles; Tumor Burden; Xenograft Model Antitumor Assays | 2009 |
The antiangiogenic agent ZD4190 prevents tumour outgrowth in a model of minimal residual carcinoma in deep tissues.
Topics: Angiogenesis Inhibitors; Animals; Disease Models, Animal; Female; Mice; Mice, Inbred C57BL; Neoplasm, Residual; Neoplasms, Experimental; Quinazolines; Triazoles; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factor Receptor-2 | 2009 |
Efficacy of albaconazole against Candida albicans in a vaginitis model.
Topics: Administration, Oral; Animals; Antifungal Agents; Candida albicans; Female; Fluconazole; Mice; Mice, Inbred BALB C; Quinazolines; Triazoles; Vaginitis | 2009 |
3-(5-Nitro-2-thienyl)-9-chloro-5-morpholin-4-yl[1,2,4]triazolo[4,3-c]quinazoline induces ROS-mitochondrial mediated death signaling and activation of p38 MAPK in murine L1210 leukemia cells.
Topics: Animals; Apoptosis; Caspase 3; Cytochromes c; Enzyme Activation; JNK Mitogen-Activated Protein Kinases; Leukemia L1210; Membrane Potential, Mitochondrial; Mice; Mitochondria; Molecular Structure; p38 Mitogen-Activated Protein Kinases; Poly(ADP-ribose) Polymerases; Quinazolines; Reactive Oxygen Species; Signal Transduction; Triazoles | 2009 |
How to treat hormone receptor-positive, human epidermal growth factor receptor 2-amplified breast cancer.
Topics: Anastrozole; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Lapatinib; Nitriles; Prognosis; Quinazolines; Randomized Controlled Trials as Topic; Receptor, ErbB-2; Receptors, Estrogen; Risk Assessment; Survival Analysis; Time Factors; Trastuzumab; Triazoles | 2009 |
Adenosine blocks IFN-gamma-induced phosphorylation of STAT1 on serine 727 to reduce macrophage activation.
Topics: Adenosine; Adenosine A3 Receptor Antagonists; Analgesics; Animals; Cell Line; Dihydropyridines; Gene Expression; Humans; Interferon-gamma; Janus Kinases; Macrophage Activation; Macrophages; Mice; Microarray Analysis; Phosphorylation; Quinazolines; Receptor, Adenosine A3; Serine; Signal Transduction; STAT1 Transcription Factor; Transcriptional Activation; Triazoles; Tyrosine | 2009 |
Synthesis, cytotoxicity by bioluminescence inhibition, antibacterial and antifungal activity of ([1,2,4]Triazolo[1,5-c]quinazolin-2-ylthio)carboxylic acid amides.
Topics: Amides; Anti-Bacterial Agents; Antifungal Agents; Bacteria; Fungi; Luminescent Proteins; Microbial Sensitivity Tests; Molecular Structure; Quinazolines; Triazoles | 2009 |
Click chemistry: studies on the synthesis of novel fluorous tagged triazol-4-yl substituted quinazoline derivatives and their biological evaluation--theoretical and experimental validation.
Topics: Anti-Infective Agents; Bacteria; Fungi; Microbial Sensitivity Tests; Models, Molecular; Molecular Conformation; Quinazolines; Reproducibility of Results; Thermodynamics; Triazoles | 2010 |
Increased cytotoxicity of an unusual DNA topoisomerase II inhibitor compound C-1305 toward HeLa cells with downregulated PARP-1 activity results from re-activation of the p53 pathway and modulation of mitotic checkpoints.
Topics: Acridines; Apoptosis; Blotting, Western; Cell Cycle; Cell Death; Cyclin B1; DNA Damage; Dose-Response Relationship, Drug; Down-Regulation; Flow Cytometry; Gene Expression Regulation; HeLa Cells; Humans; Mitosis; Poly (ADP-Ribose) Polymerase-1; Poly(ADP-ribose) Polymerase Inhibitors; Poly(ADP-ribose) Polymerases; Polyploidy; Proteasome Endopeptidase Complex; Quinazolines; Topoisomerase II Inhibitors; Triazoles; Tumor Suppressor Protein p53 | 2010 |
The role of adenosine receptors in regulating production of tumour necrosis factor-alpha and chemokines by human lung macrophages.
Topics: Acetamides; Cells, Cultured; Chemokines; Female; Humans; Lipopolysaccharides; Lung; Macrophages, Alveolar; Male; Middle Aged; Protein Subunits; Purinergic P1 Receptor Agonists; Purinergic P1 Receptor Antagonists; Purines; Quinazolines; Receptors, Purinergic P1; Reverse Transcriptase Polymerase Chain Reaction; Triazines; Triazoles; Tumor Necrosis Factor-alpha | 2010 |
Breast cancer drug approved for new indication.
Topics: Antineoplastic Agents; Breast Neoplasms; Drug Administration Schedule; Drug Approval; Drug Therapy, Combination; Female; Humans; Lapatinib; Letrozole; Neoplasms, Hormone-Dependent; Nitriles; Postmenopause; Quinazolines; Triazoles; United States; United States Food and Drug Administration; Women's Health | 2010 |
Synthesis and biological activities of some novel triazoloquinazolines and triazinoquinazolines containing benzenesulfonamide moieties.
Topics: Acetaminophen; Analgesics, Non-Narcotic; Animals; Anti-Inflammatory Agents, Non-Steroidal; Body Temperature; Edema; Foot; Formaldehyde; Indicators and Reagents; Lethal Dose 50; Magnetic Resonance Spectroscopy; Male; Mass Spectrometry; Mice; Quinazolines; Rats; Rats, Wistar; Spectrophotometry, Infrared; Sulfonamides; Triazines; Triazoles | 2010 |
MET kinase inhibitor SGX523 synergizes with epidermal growth factor receptor inhibitor erlotinib in a hepatocyte growth factor-dependent fashion to suppress carcinoma growth.
Topics: Animals; Carcinoma; Cell Cycle; Cell Growth Processes; Drug Synergism; ErbB Receptors; Erlotinib Hydrochloride; Female; Hepatocyte Growth Factor; Humans; Mice; Mice, Inbred C3H; Mice, SCID; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-met; Pyridazines; Quinazolines; Receptors, Growth Factor; Triazoles; Xenograft Model Antitumor Assays | 2010 |
The Axl receptor tyrosine kinase is an adverse prognostic factor and a therapeutic target in esophageal adenocarcinoma.
Topics: Adenocarcinoma; Aged; Animals; Axl Receptor Tyrosine Kinase; Barrett Esophagus; Benzocycloheptenes; Cell Movement; Esophageal Neoplasms; Female; Humans; Immunoenzyme Techniques; Intercellular Signaling Peptides and Proteins; Lapatinib; Lymphatic Metastasis; Male; Mice; Mice, Inbred NOD; Mice, SCID; Middle Aged; Phosphorylation; Protein Kinase Inhibitors; Proto-Oncogene Proteins; Quinazolines; ral GTP-Binding Proteins; Receptor Protein-Tyrosine Kinases; RNA, Small Interfering; Signal Transduction; Survival Rate; Triazoles | 2010 |
ABC transporters required for export of wall teichoic acids do not discriminate between different main chain polymers.
Topics: ATP-Binding Cassette Transporters; Bacillus subtilis; Cell Wall; Cloning, Molecular; Methicillin-Resistant Staphylococcus aureus; Peptidoglycan; Quinazolines; Staphylococcus aureus; Teichoic Acids; Triazoles | 2011 |
Inhibition of neutrophil infiltration into A549 lung tumors in vitro and in vivo using a CXCR2-specific antagonist is associated with reduced tumor growth.
Topics: Adenocarcinoma; Animals; Blotting, Western; Cell Proliferation; Chemotaxis; Culture Media, Conditioned; Enzyme-Linked Immunosorbent Assay; Humans; Immunoenzyme Techniques; In Vitro Techniques; Lung Neoplasms; Melanoma; Mice; Mice, Inbred BALB C; Mice, SCID; Neutrophil Infiltration; Quinazolines; Receptors, Interleukin-8B; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Spheroids, Cellular; Triazoles; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2011 |
PET imaging of early response to the tyrosine kinase inhibitor ZD4190.
Topics: Animals; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Down-Regulation; Female; Glucose; Humans; Integrin alphaVbeta3; Mice; Positron-Emission Tomography; Protein Kinase Inhibitors; Quinazolines; Radioactive Tracers; Time Factors; Treatment Outcome; Triazoles; Vascular Endothelial Growth Factor Receptor-2; Xenograft Model Antitumor Assays | 2011 |
Bicyclic 1,2,3-triazolium ionic liquids: synthesis, characterization, and application to rutaecarpine synthesis.
Topics: Bridged Bicyclo Compounds, Heterocyclic; Indole Alkaloids; Ionic Liquids; Molecular Structure; Quinazolines; Triazoles | 2011 |
Neoadjuvant chemotherapy and targeted therapies: a promising strategy.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Chemotherapy, Adjuvant; Disease-Free Survival; DNA Repair; Drug Discovery; Everolimus; Female; Genetic Predisposition to Disease; Humans; Lapatinib; Letrozole; Molecular Targeted Therapy; Neoadjuvant Therapy; Nitriles; Quinazolines; Randomized Controlled Trials as Topic; Receptor, ErbB-2; Receptors, Estrogen; Sirolimus; Trastuzumab; Triazoles | 2011 |
Endocrine therapy, new biologicals, and new study designs for presurgical studies in breast cancer.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Chemotherapy, Adjuvant; Clinical Trials as Topic; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Ki-67 Antigen; Lapatinib; Molecular Targeted Therapy; Multicenter Studies as Topic; Neoadjuvant Therapy; Nitriles; Predictive Value of Tests; Preoperative Period; Quinazolines; Receptors, Estrogen; Receptors, Progesterone; Tamoxifen; Treatment Outcome; Triazoles | 2011 |
Effects of DPP-4 inhibitors on the heart in a rat model of uremic cardiomyopathy.
Topics: Animals; Area Under Curve; Cardiomyopathies; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Disease Models, Animal; Gene Expression Regulation; Glomerular Filtration Rate; Glucagon-Like Peptide 1; Heart; Humans; Kidney Failure, Chronic; Linagliptin; Myocardium; Natriuretic Peptide, Brain; Nephrectomy; Piperidines; Purines; Pyrazines; Quinazolines; Rats; Reverse Transcriptase Polymerase Chain Reaction; Sitagliptin Phosphate; Triazoles; Uracil; Uremia | 2011 |
Synthesis and analgesic activity of some new pyrazoles and triazoles bearing a 6,8-dibromo-2-methylquinazoline moiety.
Topics: Analgesics; Animals; Female; Male; Mice; Pyrazoles; Quinazolines; Triazoles | 2011 |
The effect of adenosine on pro-inflammatory cytokine production by porcine T cells.
Topics: Adenosine; Adenosine-5'-(N-ethylcarboxamide); Animals; CD3 Complex; CD4-Positive T-Lymphocytes; CD8-Positive T-Lymphocytes; Concanavalin A; Dose-Response Relationship, Drug; Flow Cytometry; Inflammation; Interferon-gamma; Interleukin-10; Interleukin-2; Quinazolines; Swine; T-Lymphocyte Subsets; T-Lymphocytes; Triazoles; Tumor Necrosis Factor-alpha | 2012 |
An antibiotic that inhibits a late step in wall teichoic acid biosynthesis induces the cell wall stress stimulon in Staphylococcus aureus.
Topics: Anti-Bacterial Agents; Autolysis; Bacterial Proteins; beta-Lactams; Cell Wall; Culture Media; Methicillin-Resistant Staphylococcus aureus; Microarray Analysis; Microbial Sensitivity Tests; Microscopy, Electron; Microscopy, Electron, Transmission; Quinazolines; RNA, Bacterial; Staphylococcus aureus; Teichoic Acids; Transcription, Genetic; Triazoles; Virulence Factors | 2012 |
Computer-aided drug design of falcipain inhibitors: virtual screening, structure-activity relationships, hydration site thermodynamics, and reactivity analysis.
Topics: Binding Sites; Cysteine Endopeptidases; Drug Design; Drug Evaluation, Preclinical; Humans; Models, Molecular; Molecular Conformation; Protease Inhibitors; Protein Conformation; Quinazolines; Small Molecule Libraries; Structure-Activity Relationship; Tetrazoles; Thermodynamics; Triazoles; User-Computer Interface; Water | 2012 |
Novel fluorescent antagonist as a molecular probe in A(3) adenosine receptor binding assays using flow cytometry.
Topics: Adenosine A3 Receptor Antagonists; Animals; CHO Cells; Cricetinae; Flow Cytometry; Fluorescence; Models, Chemical; Models, Molecular; Molecular Structure; Protein Binding; Protein Conformation; Pyrazoles; Pyridines; Quinazolines; Receptor, Adenosine A3; Structure-Activity Relationship; Triazoles | 2012 |
Dual inhibitor of PDE7 and GSK-3-VP1.15 acts as antipsychotic and cognitive enhancer in C57BL/6J mice.
Topics: Animals; Antipsychotic Agents; Behavior, Animal; Cognition Disorders; Cyclic Nucleotide Phosphodiesterases, Type 7; Dose-Response Relationship, Drug; Drugs, Investigational; Enzyme Inhibitors; Glycogen Synthase Kinase 3; Male; Memory; Mice; Mice, Inbred C57BL; Molecular Targeted Therapy; Neural Inhibition; Nootropic Agents; Phosphodiesterase Inhibitors; Quinazolines; Schizophrenia; Spatial Behavior; Triazoles | 2013 |
[Therapeutic use and adverse events of incretin-related drugs].
Topics: Adamantane; Aged; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Exenatide; Glucagon-Like Peptide 1; Humans; Hypoglycemic Agents; Incretins; Linagliptin; Liraglutide; Nitriles; Peptides; Piperidines; Purines; Pyrazines; Pyrrolidines; Quinazolines; Sitagliptin Phosphate; Triazoles; Uracil; Venoms; Vildagliptin | 2012 |
Anti-proliferative effect of cytohesin inhibition in gefitinib-resistant lung cancer cells.
Topics: Animals; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Cytoplasm; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; ErbB Receptors; Gefitinib; Gene Expression Regulation, Neoplastic; Guanine Nucleotide Exchange Factors; Humans; Lung Neoplasms; Male; Mice; Mice, Nude; Neoplasm Transplantation; Quinazolines; Receptor, IGF Type 1; Signal Transduction; Triazoles | 2012 |
Reactive oxygen species contribute to the promotion of the ATP-mediated proliferation of mouse skeletal myoblasts.
Topics: Adenosine Triphosphate; Animals; Calcium; Catalase; Cell Proliferation; Hydrogen Peroxide; Male; Mice; Mice, Inbred BALB C; Myoblasts, Skeletal; Primary Cell Culture; Purinergic P1 Receptor Antagonists; Purinergic P2 Receptor Antagonists; Quinazolines; Reactive Oxygen Species; Receptors, Purinergic P1; Receptors, Purinergic P2; Signal Transduction; Suramin; Triazoles | 2012 |
The synergistic effect of EGFR tyrosine kinase inhibitor gefitinib in combination with aromatase inhibitor anastrozole in non-small cell lung cancer cell lines.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Carcinoma, Non-Small-Cell Lung; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Drug Synergism; ErbB Receptors; Estrogen Receptor alpha; Estrogen Receptor beta; Extracellular Signal-Regulated MAP Kinases; Gefitinib; Gene Expression; Humans; Inhibitory Concentration 50; Lung Neoplasms; MAP Kinase Signaling System; Nitriles; Protein Kinase Inhibitors; Protein Transport; Proto-Oncogene Proteins c-akt; Quinazolines; Triazoles | 2012 |
Multiple analyses of G-protein coupled receptor (GPCR) expression in the development of gefitinib-resistance in transforming non-small-cell lung cancer.
Topics: Adenosine A2 Receptor Antagonists; Antineoplastic Agents; Blotting, Western; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Survival; Cells, Cultured; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Fibroblasts; Gefitinib; Humans; Lung; Lung Neoplasms; Oligonucleotide Array Sequence Analysis; Pyrimidines; Quinazolines; Receptor, Adenosine A2A; Receptors, G-Protein-Coupled; Reverse Transcriptase Polymerase Chain Reaction; RNA Interference; Transcriptome; Triazoles | 2012 |
Identification of a small molecule PriA helicase inhibitor.
Topics: Adenosine Triphosphate; Binding Sites; DNA Helicases; DNA-Binding Proteins; Enzyme Inhibitors; Escherichia coli Proteins; Inhibitory Concentration 50; Kinetics; Neisseria gonorrhoeae; Protein Conformation; Quinazolines; Triazoles | 2012 |
Synthesis and anticonvulsant activity evaluation of 5-phenyl-[1,2,4]triazolo[4,3-c]quinazolin-3-amines.
Topics: Amines; Animals; Anticonvulsants; Drug Design; Electroshock; Mice; Mice, Inbred Strains; Molecular Structure; Neurotoxicity Syndromes; Quinazolines; Rotarod Performance Test; Seizures; Triazoles | 2013 |
Synthesis, fungicidal activity, and sterol 14α-demethylase binding interaction of 2-azolyl-3,4-dihydroquinazolines on Penicillium digitatum.
Topics: Cytochrome P-450 Enzyme System; Fungicides, Industrial; Imidazoles; Penicillium; Protein Binding; Quinazolines; Sterol 14-Demethylase; Triazoles | 2013 |
Reports of pancreatitis are 20-30 times more likely with GLP-1 drugs, analysis finds.
Topics: Adamantane; Diabetes Mellitus; Dipeptides; Glucagon-Like Peptide 1; Humans; Hypoglycemic Agents; Linagliptin; Pancreatitis; Purines; Pyrazines; Quinazolines; Sitagliptin Phosphate; Triazoles; United States | 2013 |
The DPP-4 inhibitor linagliptin restores β-cell function and survival in human isolated islets through GLP-1 stabilization.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Antioxidants; Cell Survival; Cytokines; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Drug Inverse Agonism; Glucagon-Like Peptide 1; Humans; Insulin; Insulin Secretion; Insulin-Secreting Cells; Interleukin 1 Receptor Antagonist Protein; Interleukin-1beta; Linagliptin; Palmitic Acid; Peptide Fragments; Protein Stability; Purines; Pyrazines; Quinazolines; Recombinant Proteins; Sitagliptin Phosphate; Tissue Culture Techniques; Triazoles | 2013 |
Strengthening context-dependent anticancer effects on non-small cell lung carcinoma by inhibition of both MET and EGFR.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Disease Models, Animal; Drug Synergism; ErbB Receptors; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Mice; Molecular Targeted Therapy; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-met; Pyridazines; Quinazolines; Signal Transduction; Small Cell Lung Carcinoma; Triazoles; Xenograft Model Antitumor Assays | 2013 |
Regioselective synthesis of 6-aryl-benzo[h][1,2,4]-triazolo[5,1-b]quinazoline-7,8-diones as potent antitumoral agents.
Topics: Aldehydes; Antineoplastic Agents; Catalysis; Cell Line, Tumor; Hep G2 Cells; Humans; Naphthoquinones; Neoplasms; Quinazolines; Sulfonic Acids; Triazoles | 2013 |
Axl mediates acquired resistance of head and neck cancer cells to the epidermal growth factor receptor inhibitor erlotinib.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Axl Receptor Tyrosine Kinase; Benzocycloheptenes; Cell Line, Tumor; Cell Movement; Drug Resistance, Neoplasm; Erlotinib Hydrochloride; Female; Gene Expression Regulation, Neoplastic; Head and Neck Neoplasms; Humans; Male; MicroRNAs; Middle Aged; Oligonucleotide Array Sequence Analysis; Protein Kinase Inhibitors; Proto-Oncogene Proteins; Quinazolines; Receptor Protein-Tyrosine Kinases; Triazoles | 2013 |
Quantitative ER and PgR assessment as predictors of benefit from lapatinib in postmenopausal women with hormone receptor-positive, HER2-negative metastatic breast cancer.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Disease-Free Survival; Female; Humans; Immunohistochemistry; In Situ Hybridization, Fluorescence; Kaplan-Meier Estimate; Lapatinib; Letrozole; Middle Aged; Neoplasm Metastasis; Nitriles; Postmenopause; Quinazolines; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Retrospective Studies; Triazoles | 2014 |
American Society of Clinical Oncology Annual Meeting 2013.
Topics: Antibodies, Monoclonal; Antineoplastic Agents; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Docetaxel; Erlotinib Hydrochloride; Female; Humans; Imidazoles; Indoles; Lung Neoplasms; Male; Medical Oncology; Multicenter Studies as Topic; Oximes; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Quinazolines; Randomized Controlled Trials as Topic; Small Cell Lung Carcinoma; Societies, Medical; Sulfones; Sunitinib; Taxoids; Treatment Outcome; Triazoles; United States | 2013 |
Caffeine and the analog CGS 15943 inhibit cancer cell growth by targeting the phosphoinositide 3-kinase/Akt pathway.
Topics: Antineoplastic Agents; Apoptosis; Caffeine; Carcinoma, Hepatocellular; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Cell Proliferation; Humans; Liver Neoplasms; Pancreatic Neoplasms; Phosphatidylinositol 3-Kinases; Proto-Oncogene Proteins c-akt; Purinergic P1 Receptor Agonists; Quinazolines; Signal Transduction; Triazoles | 2014 |
The role of activated adenosine receptors in degranulation of human LAD2 mast cells.
Topics: Animals; Cell Line; Humans; Mast Cells; Mice; Mice, Inbred BALB C; Purinergic P1 Receptor Antagonists; Quinazolines; Receptors, Purinergic P1; Triazoles | 2014 |
Synthesis of new 1,2,3-triazol-4-yl-quinazoline nucleoside and acyclonucleoside analogues.
Topics: Antiviral Agents; Chemistry Techniques, Synthetic; Cycloaddition Reaction; Hepacivirus; Humans; Molecular Structure; Nucleosides; Quinazolines; Triazoles | 2014 |
Targeting the BET family for the treatment of leukemia.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Antineoplastic Agents; Azepines; Benzodiazepines; Cell Cycle Proteins; Cell Proliferation; Gene Expression; Humans; Leukemia; Nuclear Proteins; Protein Serine-Threonine Kinases; Quinazolines; Quinazolinones; RNA-Binding Proteins; Transcription Factors; Triazoles | 2014 |
VAV3 mediates resistance to breast cancer endocrine therapy.
Topics: Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Biomarkers, Tumor; Breast; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Cell Survival; Drug Resistance, Neoplasm; Enzyme Activators; ErbB Receptors; Erlotinib Hydrochloride; Estrogen Receptor alpha; Female; Gene Expression Regulation, Neoplastic; Genetic Association Studies; Genetic Variation; Humans; Indazoles; Letrozole; MCF-7 Cells; Nitriles; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-vav; Quinazolines; RNA Interference; RNA, Small Interfering; Tamoxifen; Toremifene; Triazoles | 2014 |
Synergistic effects of combined platelet-activating factor receptor and epidermal growth factor receptor targeting in ovarian cancer cells.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Azepines; Blotting, Western; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Drug Synergism; Enzyme Inhibitors; ErbB Receptors; Female; Humans; Immunohistochemistry; Mice; Mice, Nude; Ovarian Neoplasms; Platelet Aggregation Inhibitors; Platelet Membrane Glycoproteins; Quinazolines; Receptors, G-Protein-Coupled; Signal Transduction; Triazoles; Tyrphostins; Xenograft Model Antitumor Assays | 2014 |
Methylxanthine reversal of opioid-induced respiratory depression in the neonatal rat: mechanism and location of action.
Topics: Adenosine A1 Receptor Antagonists; Adenosine A2 Receptor Antagonists; Animals; Animals, Newborn; Apnea; Brain Stem; Carotid Body; Central Nervous System Stimulants; Enkephalin, Ala(2)-MePhe(4)-Gly(5)-; Phrenic Nerve; Quinazolines; Rats, Sprague-Dawley; Respiration; Theobromine; Theophylline; Tissue Culture Techniques; Triazoles; Xanthines | 2014 |
Chronic treatment with ticagrelor limits myocardial infarct size: an adenosine and cyclooxygenase-2-dependent effect.
Topics: 6-Ketoprostaglandin F1 alpha; Adenosine; Adenosine A1 Receptor Antagonists; Adenosine A2 Receptor Antagonists; Animals; Aspirin; Cardiotonic Agents; Clopidogrel; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Drug Evaluation, Preclinical; Enzyme Induction; Lipoxins; Male; Myocardial Infarction; Myocardial Reperfusion Injury; Nitric Oxide Synthase Type III; Pyrazoles; Quinazolines; Rats; Rats, Sprague-Dawley; Receptor, Adenosine A1; Receptor, Adenosine A2A; Ticagrelor; Ticlopidine; Triazoles; Up-Regulation | 2014 |
Significance of vascular dipeptidyl peptidase-4 inhibition on vascular protection in Zucker diabetic fatty rats.
Topics: Animals; Atherosclerosis; Blood Glucose; Carotid Arteries; Chemokine CCL2; Diabetes Mellitus, Type 2; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Disease Models, Animal; Gene Expression; Glucose Tolerance Test; In Vitro Techniques; Insulin; Linagliptin; Malondialdehyde; NADPH Oxidases; Purines; Pyrazines; Quinazolines; Rats, Zucker; Sitagliptin Phosphate; Triazoles; Vasodilation | 2014 |
Effects of NAD at purine receptors in isolated blood vessels.
Topics: Acetamides; Animals; Aorta, Thoracic; Coronary Vessels; Male; Mesenteric Arteries; NAD; Palmitoyl Coenzyme A; Purinergic P1 Receptor Antagonists; Purines; Pyrimidines; Quinazolines; Rats; Rats, Wistar; Receptors, Purinergic; Swine; Triazoles; Vasodilation | 2015 |
Gliptin and GLP-1 analog treatment improves survival and vascular inflammation/dysfunction in animals with lipopolysaccharide-induced endotoxemia.
Topics: Animals; Dipeptidyl-Peptidase IV Inhibitors; Disease Models, Animal; Endotoxemia; Glucagon-Like Peptide 1; Inflammation; Linagliptin; Lipopolysaccharides; Liraglutide; Male; Mice; Mice, Inbred C57BL; Mice, Knockout; Oxidative Stress; Purines; Pyrazines; Quinazolines; Rats; Rats, Wistar; Real-Time Polymerase Chain Reaction; Sitagliptin Phosphate; Triazoles | 2015 |
A HAMP promoter bioassay system for identifying chemical compounds that modulate hepcidin expression.
Topics: Blotting, Western; Bone Morphogenetic Protein 6; Cell Line, Tumor; Cobalt; Gene Expression; Green Fluorescent Proteins; Heparin; Hepcidins; Humans; Interleukin-6; Microscopy, Fluorescence; Oncostatin M; Organic Chemicals; Promoter Regions, Genetic; Pyrazoles; Pyrimidines; Quinazolines; Reverse Transcriptase Polymerase Chain Reaction; Signal Transduction; Small Molecule Libraries; Triazoles | 2015 |
Aurora kinase A and B as new treatment targets in aromatase inhibitor-resistant breast cancer cells.
Topics: Aromatase Inhibitors; Aurora Kinase A; Aurora Kinase B; Breast Neoplasms; Drug Resistance, Neoplasm; Estrogen Receptor alpha; Female; Gene Expression Regulation, Neoplastic; Gene Knockdown Techniques; Humans; MCF-7 Cells; Organophosphates; Quinazolines; Small Molecule Libraries; Triazoles | 2015 |
Stem cell mobilizers targeting chemokine receptor CXCR4: renoprotective application in acute kidney injury.
Topics: Acute Kidney Injury; Animals; Chemotaxis; Flow Cytometry; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cells; Humans; Male; Mice; Mice, Inbred C57BL; Quinazolines; Rats; Receptors, CXCR4; Reperfusion Injury; Signal Transduction; Triazoles | 2015 |
Use of molecular modeling aided design to dial out hERG liability in adenosine A(2A) receptor antagonists.
Topics: Adenosine A2 Receptor Antagonists; Benzopyrans; Drug Design; ERG1 Potassium Channel; Ether-A-Go-Go Potassium Channels; Humans; Molecular Docking Simulation; Piperidines; Quinazolines; Receptor, Adenosine A2A; Triazoles | 2015 |
Insights into biology of luminal HER2 vs. enriched HER2 subtypes: Therapeutic implications.
Topics: Anastrozole; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Drug Resistance, Neoplasm; Female; Humans; Lapatinib; Letrozole; Molecular Imaging; Neoadjuvant Therapy; Nitriles; Precision Medicine; Quinazolines; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Trastuzumab; Triazoles | 2015 |
c-Myc alterations confer therapeutic response and acquired resistance to c-Met inhibitors in MET-addicted cancers.
Topics: Animals; Cell Line, Tumor; Cell Proliferation; Cell Survival; Drug Resistance, Neoplasm; Gefitinib; Humans; Mice, Inbred BALB C; Mice, Nude; Molecular Targeted Therapy; Neoplasms; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-met; Proto-Oncogene Proteins c-myc; Pyridazines; Quinazolines; RNA Interference; RNA, Small Interfering; Triazoles; Xenograft Model Antitumor Assays | 2015 |
A global economic model to assess the cost-effectiveness of new treatments for advanced breast cancer in Canada.
Topics: Anastrozole; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Canada; Cost-Benefit Analysis; Disease Progression; Female; Health Services; Humans; Lapatinib; Letrozole; Markov Chains; Models, Econometric; Neoplasm Metastasis; Nitriles; Quality-Adjusted Life Years; Quinazolines; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Terminal Care; Trastuzumab; Triazoles | 2016 |
1-R-2-([1,2,4]Triazolo[1,5-c]quinazoline-2-ylthio)etanon(ol)s: Synthesis, Bioluminescence Inhibition, Molecular Docking Studies, Antibacterial and Antifungal Activities.
Topics: Anti-Bacterial Agents; Antifungal Agents; Bacteria; Bacterial Infections; Fungi; Humans; Microbial Sensitivity Tests; Molecular Docking Simulation; Mycoses; Quinazolines; Tetrahydrofolate Dehydrogenase; Triazoles | 2016 |
Antimicrobial Activity of Synthesized 2-Methylthiobenzo[g][1,2,4]- triazolo[1,5-a]quinazoline Derivatives.
Topics: Amphotericin B; Ampicillin; Anti-Bacterial Agents; Antifungal Agents; Colony Count, Microbial; Gentamicins; Gram-Negative Bacteria; Gram-Positive Bacteria; Microbial Sensitivity Tests; Mitosporic Fungi; Quinazolines; Triazoles | 2016 |
Prognostic Value of Intrinsic Subtypes in Hormone Receptor-Positive Metastatic Breast Cancer Treated With Letrozole With or Without Lapatinib.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Bone Neoplasms; Breast Neoplasms; Disease-Free Survival; Female; Humans; Kaplan-Meier Estimate; Lapatinib; Letrozole; Middle Aged; Nitriles; Prognosis; Proportional Hazards Models; Quinazolines; Receptor, ErbB-2; Retrospective Studies; Treatment Outcome; Triazoles | 2016 |
Exploiting 1,2,3-Triazolium Ionic Liquids for Synthesis of Tryptanthrin and Chemoselective Extraction of Copper(II) Ions and Histidine-Containing Peptides.
Topics: Bridged Bicyclo Compounds, Heterocyclic; Copper; Histidine; Ionic Liquids; Molecular Structure; Peptides; Quinazolines; Triazoles | 2016 |
Synthesis and investigation of novel 6-(1,2,3-triazol-4-yl)-4-aminoquinazolin derivatives possessing hydroxamic acid moiety for cancer therapy.
Topics: Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Drug Design; Drug Screening Assays, Antitumor; Green Fluorescent Proteins; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Molecular Docking Simulation; Quinazolines; Receptor, ErbB-2; Structure-Activity Relationship; Triazoles | 2017 |
A Novel CXCR4 Antagonist CX549 Induces Neuroprotection in Stroke Brain.
Topics: Animals; Anti-Inflammatory Agents; Behavior, Animal; Benzylamines; Brain; Brain Infarction; Chemotaxis; Cyclams; HEK293 Cells; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cells; Heterocyclic Compounds; Humans; Interleukin-6; Male; Mice, Inbred C57BL; Neurons; Neuroprotection; Neuroprotective Agents; Quinazolines; Rats, Sprague-Dawley; Receptors, CXCR4; Stroke; Triazoles; Tumor Necrosis Factor-alpha | 2017 |
Discovery of Novel, Highly Potent, and Selective Matrix Metalloproteinase (MMP)-13 Inhibitors with a 1,2,4-Triazol-3-yl Moiety as a Zinc Binding Group Using a Structure-Based Design Approach.
Topics: Animals; Cartilage; Cattle; Chelating Agents; Collagen; Drug Design; Matrix Metalloproteinase 13; Matrix Metalloproteinase Inhibitors; Pyrimidines; Pyrimidinones; Quinazolines; Thiophenes; Triazoles; Zinc | 2017 |
[A Case of Interstitial Pneumonitis Induced by Lapatinib plus Letrozole].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Ductal, Breast; ErbB Receptors; Female; Humans; Lapatinib; Letrozole; Lung Diseases, Interstitial; Nitriles; Quinazolines; Triazoles | 2016 |
Tumor-infiltrating lymphocytes and molecular response after neoadjuvant therapy for HR+/HER2- breast cancer: results from two prospective trials.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Chemotherapy, Adjuvant; Female; Humans; Lapatinib; Letrozole; Lymphocytes, Tumor-Infiltrating; Middle Aged; Neoadjuvant Therapy; Nitriles; Prospective Studies; Quinazolines; Receptor, ErbB-2; Receptors, Cell Surface; Treatment Outcome; Triazoles | 2017 |
Caffeine Suppresses the Activation of Hepatic Stellate Cells cAMP-Independently by Antagonizing Adenosine Receptors.
Topics: Animals; Caffeine; Cells, Cultured; Chelating Agents; Cyclic AMP; Dose-Response Relationship, Drug; Egtazic Acid; Hepatic Stellate Cells; Liver Cirrhosis; Male; MAP Kinase Signaling System; Mice; Phosphodiesterase Inhibitors; Phosphorylation; Quinazolines; Receptors, Purinergic P1; Triazoles | 2017 |
Design, synthesis, anti-inflammatory activity, and molecular docking studies of perimidine derivatives containing triazole.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Cell Survival; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cytokines; Dose-Response Relationship, Drug; Drug Design; Mice; Molecular Docking Simulation; Molecular Structure; Quinazolines; RAW 264.7 Cells; Structure-Activity Relationship; Triazoles | 2017 |
Combined BET bromodomain and CDK2 inhibition in MYC-driven medulloblastoma.
Topics: Azepines; Cell Line, Tumor; Cell Proliferation; Cell Survival; Cerebellar Neoplasms; Cyclin-Dependent Kinase 2; Drug Synergism; Female; Humans; Medulloblastoma; Piperazines; Protein Kinase Inhibitors; Protein Stability; Proto-Oncogene Proteins c-myc; Pyrazoles; Pyridines; Quinazolines; Sequence Analysis, RNA; Signal Transduction; Triazoles; Xenograft Model Antitumor Assays | 2018 |
Daily or weekly dosing with EGFR inhibitors, gefitinib and lapatinib, and AKt inhibitor MK2206 in mammary cancer models.
Topics: Animals; Disease Models, Animal; Drug Administration Schedule; ErbB Receptors; Female; Gefitinib; Heterocyclic Compounds, 3-Ring; Lapatinib; Male; Mammary Neoplasms, Experimental; Mice; Mice, Knockout; Protein Kinase Inhibitors; Quinazolines; Rats; Rats, Sprague-Dawley; Triazoles | 2018 |
Synthesis and antimicrobial evaluation of novel 1,2,4-triazole thioether derivatives bearing a quinazoline moiety.
Topics: Anti-Bacterial Agents; Antifungal Agents; Fungi; Quinazolines; Ralstonia solanacearum; Sulfides; Triazoles; Xanthomonas | 2018 |
Exposure of Staphylococcus aureus to Targocil Blocks Translocation of the Major Autolysin Atl across the Membrane, Resulting in a Significant Decrease in Autolysis.
Topics: Autolysis; Bacterial Translocation; Lysostaphin; Muramidase; N-Acetylmuramoyl-L-alanine Amidase; Protein Transport; Quinazolines; Staphylococcus aureus; Teichoic Acids; Triazoles | 2018 |
Mathematical and Structural Characterization of Strong Nonadditive Structure-Activity Relationship Caused by Protein Conformational Changes.
Topics: Binding Sites; Crystallography, X-Ray; Cyclic Nucleotide Phosphodiesterases, Type 2; Enzyme Inhibitors; Humans; Hydrophobic and Hydrophilic Interactions; Ligands; Models, Theoretical; Protein Binding; Protein Conformation; Quinazolines; Structure-Activity Relationship; Triazoles | 2018 |
anti-Selective Catalytic Asymmetric Nitroaldol Reaction of α-Keto Esters: Intriguing Solvent Effect, Flow Reaction, and Synthesis of Active Pharmaceutical Ingredients.
Topics: Alcohols; Catalysis; Esters; Furans; Ketones; Neodymium; Nitro Compounds; Quinazolines; Sodium; Solvents; Stereoisomerism; Triazoles | 2018 |
Discovery of N-(4-{[5-Fluoro-7-(2-methoxyethoxy)quinazolin-4-yl]amino}phenyl)-2-[4-(propan-2-yl)-1 H-1,2,3-triazol-1-yl]acetamide (AZD3229), a Potent Pan-KIT Mutant Inhibitor for the Treatment of Gastrointestinal Stromal Tumors.
Topics: Drug Discovery; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Models, Molecular; Mutant Proteins; Mutation; Protein Conformation; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-kit; Quinazolines; Tissue Distribution; Triazoles; Tumor Cells, Cultured | 2018 |
Design, synthesis and evaluation of novel hybrids between 4-anilinoquinazolines and substituted triazoles as potent cytotoxic agents.
Topics: Amino Acid Sequence; Aniline Compounds; Antineoplastic Agents; Cell Line, Tumor; Drug Design; Drug Screening Assays, Antitumor; ErbB Receptors; Humans; Molecular Docking Simulation; Neoplasms; Quinazolines; Sequence Alignment; Structure-Activity Relationship; Triazoles | 2018 |
An mTOR Signaling Modulator Suppressed Heterotopic Ossification of Fibrodysplasia Ossificans Progressiva.
Topics: Activin Receptors, Type I; Animals; Benzodioxoles; High-Throughput Screening Assays; Humans; Induced Pluripotent Stem Cells; Mice, SCID; Mice, Transgenic; Myositis Ossificans; Ossification, Heterotopic; Oxazoles; Pyrimidines; Quinazolines; Reproducibility of Results; Signal Transduction; TOR Serine-Threonine Kinases; Triazoles; Urea | 2018 |
A brain-penetrant triazolopyrimidine enhances microtubule-stability, reduces axonal dysfunction and decreases tau pathology in a mouse tauopathy model.
Topics: Alzheimer Disease; Animals; Axonal Transport; Axons; Brain; Disease Models, Animal; Humans; Mice; Microtubules; Neurons; Quinazolines; tau Proteins; Tauopathies; Triazoles | 2018 |
Triazoloquinazolines as a new class of potent α-glucosidase inhibitors: in vitro evaluation and docking study.
Topics: alpha-Glucosidases; Glycoside Hydrolase Inhibitors; Molecular Docking Simulation; Molecular Structure; Quinazolines; Saccharomyces cerevisiae; Structure-Activity Relationship; Triazoles | 2019 |
Discovery of structurally distinct tricyclic M
Topics: Allosteric Regulation; Animals; Drug Design; Half-Life; Humans; Inhibitory Concentration 50; Pyridazines; Quinazolines; Rats; Receptor, Muscarinic M4; Structure-Activity Relationship; Triazoles | 2020 |
The Pharmacokinetic-Pharmacodynamic (PKPD) Relationships of AZD3229, a Novel and Selective Inhibitor of KIT, in a Range of Mouse Xenograft Models of GIST.
Topics: Animals; Cell Line, Tumor; Cell Proliferation; Gastrointestinal Stromal Tumors; Humans; Mice; Models, Biological; Mutation; Phosphorylation; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-kit; Quinazolines; Receptor, Platelet-Derived Growth Factor alpha; Triazoles; Xenograft Model Antitumor Assays | 2020 |
Bacillus anthracis Responds to Targocil-Induced Envelope Damage through EdsRS Activation of Cardiolipin Synthesis.
Topics: Anti-Bacterial Agents; Bacillus anthracis; Bacterial Proteins; Cardiolipins; Cell Wall; Gene Expression Regulation, Bacterial; Gene Order; Permeability; Quinazolines; Signal Transduction; Spores, Bacterial; Transcription, Genetic; Triazoles | 2020 |
Synthesis and biological evaluation of novel quinazoline-triazole hybrid compounds with potential use in Alzheimer's disease.
Topics: Acetylcholinesterase; Alzheimer Disease; Amino Acid Sequence; Catalytic Domain; Cholinesterase Inhibitors; Click Chemistry; Drug Evaluation, Preclinical; Humans; Molecular Docking Simulation; Protein Conformation; Quinazolines; Structure-Activity Relationship; Triazoles | 2020 |
Novel scaffold hopping of potent benzothiazole and isatin analogues linked to 1,2,3-triazole fragment that mimic quinazoline epidermal growth factor receptor inhibitors: Synthesis, antitumor and mechanistic analyses.
Topics: Antineoplastic Agents; Apoptosis; Benzothiazoles; Cell Line, Tumor; Cell Proliferation; Crystallography, X-Ray; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; ErbB Receptors; Humans; Isatin; Models, Molecular; Molecular Structure; Protein Kinase Inhibitors; Quinazolines; Structure-Activity Relationship; Triazoles | 2020 |
Discovery of small-molecule inhibitors of multidrug-resistance plasmid maintenance using a high-throughput screening approach.
Topics: Amines; Aminoglycosides; Anti-Bacterial Agents; Bacterial Proteins; Benzimidazoles; beta-Lactamases; Carbapenem-Resistant Enterobacteriaceae; DNA Replication; Drug Resistance, Multiple, Bacterial; Drug Synergism; Drug Therapy, Combination; Enterobacteriaceae Infections; Escherichia coli; High-Throughput Screening Assays; Meropenem; Microbial Sensitivity Tests; Mutagenesis, Site-Directed; Plasmids; Quinazolines; Repressor Proteins; Triazoles | 2020 |
Angular Regioselectivity in the Reactions of 2-Thioxopyrimidin-4-ones and Hydrazonoyl Chlorides: Synthesis of Novel Stereoisomeric Octahydro[1,2,4]triazolo[4,3-
Topics: Chlorides; Pyrimidines; Quinazolines; Stereoisomerism; Structure-Activity Relationship; Triazoles | 2020 |
Discovery of a first-in-class CDK2 selective degrader for AML differentiation therapy.
Topics: Antineoplastic Agents; Aurora Kinase A; Cell Differentiation; Cell Line, Tumor; Cell Proliferation; Cyclin-Dependent Kinase 2; Drug Design; Drug Discovery; Gene Expression Regulation, Leukemic; Humans; Ikaros Transcription Factor; Inhibitory Concentration 50; Leukemia, Myeloid, Acute; Myeloid Progenitor Cells; Piperazines; Primary Cell Culture; Proteolysis; Pyridines; Pyrimidines; Quinazolines; Signal Transduction; Structure-Activity Relationship; Transcriptome; Triazoles | 2021 |
Discovery and Mechanistic Characterization of a Select Modulator of AhR-regulated Transcription (SMAhRT) with Anti-cancer Effects.
Topics: Animals; Antineoplastic Agents; Apoptosis; Aryl Hydrocarbon Receptor Nuclear Translocator; Cell Line, Tumor; Fas Ligand Protein; Humans; Ligands; Mice; Quinazolines; Receptors, Aryl Hydrocarbon; Signal Transduction; Small Molecule Libraries; Transcriptional Activation; Triazoles | 2021 |
Synthesis, biological evaluation and molecular docking studies of novel 1,2,3-triazole-quinazolines as antiproliferative agents displaying ERK inhibitory activity.
Topics: Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; Extracellular Signal-Regulated MAP Kinases; Humans; Molecular Docking Simulation; Molecular Structure; Protein Kinase Inhibitors; Quinazolines; Structure-Activity Relationship; Triazoles | 2021 |
From triazolophthalazines to triazoloquinazolines: A bioisosterism-guided approach toward the identification of novel PCAF inhibitors with potential anticancer activity.
Topics: Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cell Proliferation; Cell Survival; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; Humans; Molecular Docking Simulation; Molecular Structure; p300-CBP Transcription Factors; Phthalazines; Quinazolines; Structure-Activity Relationship; Triazoles | 2021 |
Inosine monophosphate and inosine differentially regulate endotoxemia and bacterial sepsis.
Topics: Adenosine A2 Receptor Antagonists; Adenosine A3 Receptor Antagonists; Animals; Disease Models, Animal; Endotoxemia; Inosine; Inosine Monophosphate; Interleukin-10; Male; Mice; Mice, Inbred C57BL; Pneumonia, Pneumococcal; Quinazolines; Receptor, Adenosine A2A; Receptor, Adenosine A2B; Receptor, Adenosine A3; Signal Transduction; Streptococcus pneumoniae; Triazoles; Tumor Necrosis Factor-alpha | 2021 |
Antiproliferative evaluations of triazoloquinazolines as classical DNA intercalators: Design, synthesis, ADMET profile, and molecular docking.
Topics: Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; DNA; Dose-Response Relationship, Drug; Doxorubicin; Drug Design; Drug Screening Assays, Antitumor; Humans; Intercalating Agents; Molecular Docking Simulation; Molecular Structure; Quinazolines; Structure-Activity Relationship; Triazoles | 2022 |
Triazoloquinazoline derived classical DNA intercalators: Design, synthesis, in silico ADME profile, docking, and antiproliferative evaluations.
Topics: Cell Proliferation; DNA; Doxorubicin; Drug Design; Humans; Intercalating Agents; Molecular Docking Simulation; Molecular Structure; Quinazolines; Structure-Activity Relationship; Triazoles | 2022 |
Phenotypic Discovery of Triazolo[1,5-
Topics: Bone Morphogenetic Protein 2; Bone Morphogenetic Proteins; Cell Differentiation; Osteogenesis; Quinazolines; Smad Proteins; Triazoles | 2022 |
Silver-Catalyzed Cascade Cyclization of Amino-
Topics: Catalysis; Cyclization; Molecular Structure; Quinazolines; Silver; Triazoles | 2022 |
Design and synthesis of a new series of hybrids of functionalised N
Topics: Antiviral Agents; Cell Line; Humans; Quinazolines; Respiratory Syncytial Virus, Human; Structure-Activity Relationship; Triazoles | 2023 |